[
    {
        "pmid": "40764298",
        "title": "Microhaplotype deep sequencing assays to capture Plasmodium vivax infection lineages.",
        "abstract": "Plasmodium vivax elimination challenged dormant liver stage hypnozoites reactivate month initial infection resulting relapses Relapsing infection confound antimalarial clinical efficacy trial due inability distinguish recurrence arising bloodstage treatment failure recrudescence reinfection relapse Genetic relatedness paired parasite isolates measured identitybydescent IBD provide important information whether individual single multiple mosquito inoculations thus informing recurrence origin developed highthroughput amplicon sequencing assay comprising 93 multiSNP microhaplotype marker determine IBD P vivax clinical isolates assay evaluated 745 global infections including 128 infection pair randomized controlled trial RCT ClinicalTrialsgov NCT01680406 Simulations demonstrate low error pairwise IBD estimation panel RMSE  012 IBDbased network illustrate strong clustering geography IBD analysis RCT demonstrates lower frequency suspected relapse recrudescence patient treated primaquine compared without primaquine impact greater paired chloroquine artemetherlumefantrine result demonstrate potential derive new information P vivax treatment transmission using IBD generated amplicon sequencing data improved timetoevent models",
        "mesh_terms": [
            "Plasmodium vivax",
            "Malaria, Vivax",
            "Humans",
            "High-Throughput Nucleotide Sequencing",
            "Antimalarials",
            "Haplotypes",
            "Polymorphism, Single Nucleotide",
            "Primaquine",
            "Chloroquine",
            "Recurrence"
        ],
        "source": "https://pubmed.ncbi.nlm.nih.gov/40764298/",
        "source_type": "Bangladesh-specific"
    },
    {
        "pmid": "40051493",
        "title": "Perception About Factors Affecting Patient Adherence With Cardiac Medicines: A Cross-Sectional Study.",
        "abstract": "Longterm medicine frequently recommended cardiovascular patient control hypertension lower heart burden Patient adherence cardiovascular medicine crucial since stopping increase risk cardiac adverse event pose bigger risk health Perception manufacturers prescribers patient taken account identify important variable positive impact patient satisfaction thereby increase adherence prescribed cardiovascular drug therapy empirical study conducted using quantitative survey method Questionnaire contained variable influencing patient compliance measured 5point Likert scale 1 istrongly disagreei 5 istrongly agreei Questions handed dropoff collect method study conducted 15 tertiary healthcare service center 18 pharmaceutical company across Dhaka district Bangladesh total 156 cardiologists 200 cardiac patient 180 marketing professional manufacturers included survey total 11 variable affect patient compliance utilized create correlation matrix subsequently carry exploratory factor analysis Hypothesis testing done using regression model Fortyeight percent respondent strongly agreed efficacy cardiac medicine influence patient compliance stakeholder 69 agreed company reputation cardiac medicine supplier important criterion Availability affordability highly positively correlated variables variable grouped four category according factor loading scores four factor medicinal issue product strategies economic issue price strategies convenience issue place strategy communication issue promotional strategies finding study contribute comprehension factor influencing patient compliance multiple dimensions Policy maker implement promote policy encourage patient adherence longterm prescription drugs",
        "mesh_terms": [],
        "source": "https://pubmed.ncbi.nlm.nih.gov/40051493/",
        "source_type": "Bangladesh-specific"
    },
    {
        "pmid": "40049185",
        "title": "Global, regional, and national prevalence of child and adolescent overweight and obesity, 1990-2021, with forecasts to 2050: a forecasting study for the Global Burden of Disease Study 2021.",
        "abstract": "Despite well documented consequence obesity childhood adolescence future risk excess body mass noncommunicable disease adulthood coordinated global action excess body mass early life still insufficient Inconsistent measurement reporting barrier specific targets resource allocation interventions Article report current estimate overweight obesity across childhood adolescence progress time forecast inform specific actions Using established methodology Global Burden Diseases Injuries Risk Factors Study 2021 modelled overweight obesity across childhood adolescence 1990 2021 forecasted 2050 Primary data model included 1321 unique measured selfreported anthropometric data source 180 country territory survey microdata reports published literature data used estimate agestandardised global regional national overweight prevalence obesity prevalence separately child young adolescent aged 514 years typically school cared child health services older adolescent aged 1524 years increasingly school cared adult services sex 204 country territory 1990 2021 Prevalence estimate 1990 2021 generated using spatiotemporal Gaussian process regression models leveraged temporal spatial correlation epidemiological trend ensure comparability result across time geography Prevalence forecast 2022 2050 generated using generalised ensemble modelling approach assuming continuation current trends every agesexlocation population across time 19902050 estimated obesity vs overweight predominance using log ratio obesity percentage overweight percentage 1990 2021 combined prevalence overweight obesity child adolescent doubled obesity alone tripled 2021 93·1 million 95 uncertainty interval 89·696·6 individual aged 514 year 80·6 million 78·283·3 aged 1524 year obesity superregion level 2021 prevalence overweight obesity highest north Africa Middle East eg United Arab Emirates Kuwait greatest increase 1990 2021 seen southeast Asia east Asia Oceania eg Taiwan province China Maldives China 2021 female age groups many country Australasia eg Australia highincome North America eg Canada already transitioned obesity predominance male female number country north Africa Middle East eg United Arab Emirates Qatar Oceania eg Cook Islands American Samoa 2022 2050 global increase overweight not obesity prevalence forecasted stabilise yet increase absolute proportion global population obesity forecasted greater 1990 2021 substantial increase forecast 2022 2030 continue 2031 2050 2050 superregion obesity prevalence forecasted remain highest north Africa Middle East eg United Arab Emirates Kuwait forecasted increase obesity still expected largest across southeast Asia east Asia Oceania eg TimorLeste North Korea also south Asia eg Nepal Bangladesh Compared aged 1524 years superregions except Latin America Caribbean highincome superregion greater proportion aged 514 year forecasted obesity overweight 2050 Globally 15·6 12·717·2 aged 514 year forecasted obesity 2050 186 million 141221 compared 14·2 11·415·7 aged 1524 year 175 million 136203 forecasted 2050 young male aged 514 years living obesity 16·5 13·318·3 overweight 12·9 12·213·6 female aged 524 years older male aged 1524 years overweight remain prevalent obesity regional level following population forecast transitioned obesity vs overweight predominance 204150 child adolescent males female aged 524 years north Africa Middle East Tropical Latin America male aged 514 year east Asia central southern subSaharan Africa central Latin America female aged 514 year Australasia female aged 1524 year Australasia highincome North America southern subSaharan Africa male aged 1524 year highincome North America overweight obesity increased substantially every world region 1990 2021 suggesting current approach curbing increase overweight obesity failed generation child adolescents Beyond 2021 overweight childhood adolescence forecast stabilise due increase population obesity Increases obesity expected continue population world regions substantial change forecasted occur 2022 2030 immediate action needed address public health crisis Bill  Melinda Gates Foundation Australian National Health Medical Research Council",
        "mesh_terms": [
            "Humans",
            "Adolescent",
            "Child",
            "Prevalence",
            "Female",
            "Male",
            "Forecasting",
            "Global Burden of Disease",
            "Pediatric Obesity",
            "Child, Preschool",
            "Young Adult",
            "Global Health",
            "Overweight",
            "Risk Factors"
        ],
        "source": "https://pubmed.ncbi.nlm.nih.gov/40049185/",
        "source_type": "Bangladesh-specific"
    },
    {
        "pmid": "40000077",
        "title": "mHealth intervention (mTB-Tobacco) for smoking cessation in people with drug-sensitive pulmonary tuberculosis in Bangladesh and Pakistan: protocol for an adaptive design, cluster randomised controlled trial (Quit4TB).",
        "abstract": "People tuberculosis TB continue smoke likely poor health outcome quit Established smoking cessation approach mHealth may help patient TB quit smoking paper summarises methodology proposed assess effectiveness costeffectiveness mTBTobacco an mHealth intervention helping patient TB stop smoking improved health outcomes twoarm parallel openlabel multicentre cluster randomised twostage adaptive design trial proposed first evaluate superiority mTBTobacco compared usual care noninferiority mTBtobacco compared facetoface behaviour support Study setting include TB treatment centre Bangladesh Pakistan study population includes adult patients newly diagnosed within 4 weeks pulmonary TB disease daily smokers willing quit access mobile phones primary outcome includes biochemically verified continuous smoking abstinence assessed 6 month per Russell Standard generalised linear mixedeffects model used assess impact mTBTobacco intervention continuous outcomes incorporating fixed effect intervention random effect cluster relevant covariates Costeffectiveness analysis done estimate cost per quitter cost per qualityadjusted life year gained calculate incremental costeffectiveness ratio establish value money mTBTobacco trial conducted compliance International Council Harmonisation  Good Clinical Practice guideline Declaration Helsinki study approved ethic committee University Edinburgh Medical School Research Ethics Committee EMREC UK Bangladesh Medical Research Council BMRC National Bioethics Committee PMRC Pakistan result trial disseminated peerreviewed journal presented academic conferences ISRCTN86971818 httpsdoiorg101186ISRCTN86971818 preenrolment submission date 29 August 2023 registration date 11 September 2023",
        "mesh_terms": [
            "Humans",
            "Bangladesh",
            "Smoking Cessation",
            "Tuberculosis, Pulmonary",
            "Pakistan",
            "Telemedicine",
            "Cost-Benefit Analysis",
            "Randomized Controlled Trials as Topic",
            "Multicenter Studies as Topic",
            "Adult",
            "Female",
            "Male"
        ],
        "source": "https://pubmed.ncbi.nlm.nih.gov/40000077/",
        "source_type": "Bangladesh-specific"
    },
    {
        "pmid": "39890793",
        "title": "Investigating new drugs from marine seaweed metabolites for cervical cancer therapy by molecular dynamic modeling approach.",
        "abstract": "etiology cervical cancer woman attributed continuous infection human papillomavirus HPV high cost side effect standard treatment limited efficacy HPV vaccination led quest novel costeffective cervical cancer treatments particularly middle lowincome countries Therefore objective evaluate capacity marine seaweed compound hinder activity cervical cancer E6 Oncoprotein Seaweed Metabolite Database evaluated ability inhibit E6 Oncoprotein function high throughput virtual screening investigation included molecular docking ADMET test MD simulation MMGBSA analysis identify three lead seaweed druglike compounds BC008 89 kcalmol RL379 89 kcalmol BC014 87 kcalmol leading candidate positive characteristic term pharmacokinetics pharmacodynamics toxicity molecular dynamic simulation apoprotein control drug lead compound revealed superior structural stability uniformity main drug candidates MMGBSA study revealed BC008protein complex exhibited significant free binding energy value 5741 kcalmol end finding derived investigation might provide basis developing innovative anticancer treatments",
        "mesh_terms": [
            "Seaweed",
            "Uterine Cervical Neoplasms",
            "Molecular Dynamics Simulation",
            "Female",
            "Humans",
            "Molecular Docking Simulation",
            "Antineoplastic Agents",
            "Oncogene Proteins, Viral"
        ],
        "source": "https://pubmed.ncbi.nlm.nih.gov/39890793/",
        "source_type": "Bangladesh-specific"
    },
    {
        "pmid": "39820032",
        "title": "Development of a broad-spectrum epitope-based vaccine against Streptococcus pneumoniae.",
        "abstract": "Streptococcus pneumoniae SPN significant pathogen causing pneumonia meningitis particularly vulnerable population like child elderly Available pneumonia vaccine limitation since cover particular serotypes high production costs emergence antibioticresistant SPN strain underscore need new costeffective broadspectrum vaccine Two potential vaccine candidates CbpA PspA identified Bcell CTL HTL epitope predicted connected suitable linkers adjivant PADRE sequence vaccine construct found antigenic nontoxic nonallergenic soluble threedimensional structure vaccine candidate built validated Docking analysis vaccine candidate ClusPro demonstrated robust stable binding interaction MEV tolllike receptor 4 human animals iMOD server Amber v22 tool verified stability docking complexes GenScript server confirmed high efficiency cloning construct insilico cloning pET28a  vector using SnapGene demonstrating successful translation epitope region Immunological response shown enhanced CIMMSIM server study introduced strong peptide vaccine candidate potential contribute development rapid costeffective solution combating SPN However experimental verification necessary evaluate vaccines effectiveness",
        "mesh_terms": [
            "Streptococcus pneumoniae",
            "Pneumococcal Infections",
            "Epitopes",
            "Bacterial Proteins",
            "Antigens, Bacterial",
            "Pneumococcal Vaccines",
            "Vaccine Development",
            "Molecular Docking Simulation",
            "Toll-Like Receptor 4",
            "Computational Biology",
            "Humans",
            "Animals",
            "Mice"
        ],
        "source": "https://pubmed.ncbi.nlm.nih.gov/39820032/",
        "source_type": "Bangladesh-specific"
    },
    {
        "pmid": "39645377",
        "title": "Burden of disease scenarios by state in the USA, 2022-50: a forecasting analysis for the Global Burden of Disease Study 2021.",
        "abstract": "capacity anticipate future health issue important policy maker practitioner USA insight facilitate effective planning investment implementation strategies Forecasting trend disease injury burden crucial policy maker also garner substantial interest general populace lead betterinformed public integration new data sources refinement methodologies inclusion additional causes improved previous forecasting effort within scope Global Burden Diseases Injuries Risk Factors Study GBD produce forecast state national level USA various possible scenarios developed comprehensive framework forecasting life expectancy healthy life expectancy HALE causespecific mortality disabilityadjusted lifeyears DALYs due 359 cause disease injury burden 2022 2050 USA 50 state Washington DC Using GBD 2021 Future Health Scenarios modelling framework forecasted driver disease demographic drivers risk factors temperature particulate matter mortality year life lost YLL population nonfatal burden addition reference scenario representing probable future trajectory explored various future scenario potential impact next several decade human health alternative scenario comprised four risk elimination scenario including safer environment improved behavioural metabolic risks improved childhood nutrition vaccination combined scenario three USAspecific scenario based risk exposure attributable burden bestperforming US state improved high adult BMI high fasting plasma glucose FPG improved smoking improved drug use encompassing opioids cocaine amphetamine others Life expectancy USA projected increase 78·3 year 95 uncertainty interval 78·178·5 2022 79·9 year 79·580·2 2035 80·4 year 79·881·0 2050 sex combined increase forecasted modest compared country around world resulting USA declining global rank 202250 forecasted period among 204 country territory GBD 49th 66th projected decline female life expectancy West Virginia 1990 2050 little change Arkansas Oklahoma Additionally 2023 projected almost change female life expectancy many states notably Oklahoma South Dakota Utah Iowa Maine Wisconsin Female HALE projected decline 1990 2050 20 state remain unchanged three others Drug use disorder low back pain projected leading Level 3 cause agestandardised DALYs 2050 agestandardised DALY rate due drug use disorder projected increase considerably 2022 2050 19·5 6·934·1 combined risk elimination scenario show USA could gain 3·8 additional year 3·64·0 life expectancy 4·1 additional year 3·94·3 HALE 2050 versus reference scenario Using USAspecific scenarios forecasted USA could gain 0·4 additional year 0·30·6 life expectancy 0·6 additional year 0·50·8 HALE 2050 improved drug use scenario relative reference scenario Life expectancy HALE likewise projected 0·40·5 year higher 2050 improved adult BMI FPG improved smoking scenario compared reference scenario However increase scenario would substantially improve USAs global ranking 2050 from 66th 204 life expectancy reference scenario 63rd64th three USAspecific scenarios indicating USAs bestperforming state still lagging behind country rank throughout forecasted period Regardless estimated 12·4 million 11·313·5 death could averted 2022 2050 USA follow combined scenario trajectory rather reference scenario would also 1·4 million 0·72·2 fewer death 28year forecasted period improved adult BMI FPG 2·1 million 1·32·9 fewer death improved exposure smoking 1·2 million 0·91·5 fewer death lower rate drug use deaths finding highlight alarming trajectory health challenge USA which left unaddressed could lead reversal health progress made past three decade US state decline global health standing states evidence alternative scenario along published study suggests collaborative evidencebased strategies opportunity change trajectory health outcome USA investing scientific innovation healthcare access preventive health care risk exposure reduction education forecast clearly show time act now future countrys health wellbeingas well prosperity leadership position science innovationare stake Bill  Melinda Gates Foundation",
        "mesh_terms": [
            "Adult",
            "Aged",
            "Female",
            "Humans",
            "Male",
            "Middle Aged",
            "Cause of Death",
            "Disability-Adjusted Life Years",
            "Forecasting",
            "Life Expectancy",
            "Risk Factors",
            "United States",
            "Cost of Illness",
            "Population Health"
        ],
        "source": "https://pubmed.ncbi.nlm.nih.gov/39645377/",
        "source_type": "Bangladesh-specific"
    },
    {
        "pmid": "39547912",
        "title": "Using digital health technologies to optimise antimicrobial use globally.",
        "abstract": "Digital health technology DHT describes tool device generate process health data application DHTs could improve diagnosis treatment surveillance bacterial infection prevention antimicrobial resistance AMR DHTs optimise antimicrobial use rapidly developed support global adoption DHTs opportunity offered optimise antimicrobial use consensus needed data required support antimicrobial decision making Series paper explore bacterial AMR human need optimise antimicrobial use response global threat also describe stateoftheart DHTs optimise antimicrobial prescribing highincome lowincome middleincome countries consider fundamental data ideally required technology support optimised antimicrobial use",
        "mesh_terms": [
            "Humans",
            "Digital Technology",
            "Global Health",
            "Biomedical Technology",
            "Anti-Bacterial Agents",
            "Anti-Infective Agents",
            "Drug Resistance, Bacterial",
            "Antimicrobial Stewardship",
            "Bacterial Infections",
            "Digital Health"
        ],
        "source": "https://pubmed.ncbi.nlm.nih.gov/39547912/",
        "source_type": "Bangladesh-specific"
    },
    {
        "pmid": "39454232",
        "title": "Global, regional, and national burden of injuries, and burden attributable to injuries risk factors, 1990 to 2019: results from the Global Burden of Disease study 2019.",
        "abstract": "study trend current situation injury burden well attributable burden injury risk factor global regional national level based Global Burden Diseases Injuries Risk Factors Study GBD 2019 presented assess attributable burden injury risk factors data interest data source retrieved Global Health Data Exchange GHDx analyzed Causespecific death injury estimated using Cause Death Ensemble model GBD 2019 burden attributable injury risk factor incorporated population attributable fraction estimate total attributable death disabilityadjusted life years Sociodemographic Index SDI used evaluate countries developmental status Globally 7139 million 95 uncertainty interval UI 6638 7669 injury incidence 43 million UI 39 46 death caused injury 2019 inverse relationship agestandardized disabilityadjusted life year rate SDI quintiles 2019 Overall low bone mineral density leading risk factor injury death 2019 contribution 105 UI 90 116 total injury agestandardized deaths followed occupational risk 70 UI 6379 alcohol use 68 UI 52 85 Various risk responsible imposed burden injuries study highlighted small persistent share injury global burden disease injury provide beneficial data produce proper policy reach effective global injury prevention plan",
        "mesh_terms": [
            "Humans",
            "Global Burden of Disease",
            "Wounds and Injuries",
            "Risk Factors",
            "Male",
            "Female",
            "Global Health",
            "Adult",
            "Middle Aged",
            "Disability-Adjusted Life Years",
            "Adolescent",
            "Young Adult",
            "Aged",
            "Child, Preschool",
            "Infant",
            "Child",
            "Cause of Death",
            "Incidence",
            "Cost of Illness"
        ],
        "source": "https://pubmed.ncbi.nlm.nih.gov/39454232/",
        "source_type": "Bangladesh-specific"
    },
    {
        "pmid": "39366729",
        "title": "Forecasting the effects of smoking prevalence scenarios on years of life lost and life expectancy from 2022 to 2050: a systematic analysis for the Global Burden of Disease Study 2021.",
        "abstract": "Smoking leading behavioural risk factor mortality globally accounting 175 million death nearly 4·30 billion year life lost YLLs 1990 2021 pace decline smoking prevalence slowed recent year many countries although strategy recently proposed achieve tobaccofree generations none implemented date Assessing could happen current trend smoking prevalence persist could happen additional smoking prevalence reduction occur important communicating effect potential smoking policies analysis use Institute Health Metrics Evaluations Future Health Scenarios platform forecast effect three smoking prevalence scenario allcause causespecific YLLs life expectancy birth 2050 YLLs computed scenario using Global Burden Disease Study 2021 reference life table forecast causespecific mortality scenario reference scenario forecast could occur past smoking prevalence risk factor trend continue Tobacco Smoking Elimination 2023 Elimination2023 scenario quantifies maximum potential future health benefit assuming zero percent smoking prevalence 2023 onwards whereas Tobacco Smoking Elimination 2050 Elimination2050 scenario provides estimate country considering policy steadily reduce smoking prevalence 5 Together scenario underscore magnitude health benefit could reached 2050 country take decisive action eliminate smoking 95 uncertainty interval UI estimate based 2·5th 97·5th percentile draw carried multistage computational framework Global agestandardised smoking prevalence estimated 28·5 95 UI 27·929·1 among male 5·96 5·766·21 among female 2022 reference scenario smoking prevalence declined 25·9 25·226·6 among males 30·0 26·132·1 among female 2022 2050 scenario forecast cumulative 29·3 billion 95 UI 26·832·4 overall YLLs among male 22·2 billion 20·124·6 YLLs among female period Life expectancy birth scenario would increase 73·6 year 95 UI 72·874·4 2022 78·3 year 75·980·3 2050 Elimination2023 scenario forecast 2·04 billion 95 UI 1·902·21 fewer cumulative YLLs 2050 compared reference scenario life expectancy birth would increase 77·6 year 95 UI 75·179·6 among male 81·0 year 78·583·1 among females Elimination2050 scenario forecast 735 million 675808 141 million 131154 cumulative YLLs would avoided among male females respectively Life expectancy 2050 would increase 77·1 year 95 UI 74·679·0 among male 80·8 year 78·382·9 among females Existing tobacco policy must maintained smoking prevalence continue decline forecast reference scenario addition substantial smokingattributable burden avoided accelerating pace smoking elimination Implementation new tobacco control policy crucial avoiding additional smokingattributable burden coming decade ensure gain past three decade lost Bloomberg Philanthropies Bill  Melinda Gates Foundation",
        "mesh_terms": [
            "Humans",
            "Life Expectancy",
            "Forecasting",
            "Smoking",
            "Prevalence",
            "Female",
            "Male",
            "Global Burden of Disease",
            "Adult",
            "Middle Aged",
            "Global Health",
            "Aged",
            "Young Adult",
            "Adolescent"
        ],
        "source": "https://pubmed.ncbi.nlm.nih.gov/39366729/",
        "source_type": "Bangladesh-specific"
    },
    {
        "pmid": "39304265",
        "title": "Global, regional, and national burden of stroke and its risk factors, 1990-2021: a systematic analysis for the Global Burden of Disease Study 2021.",
        "abstract": "Uptodate estimate stroke burden attributable risk trend global regional national level essential evidencebased health care prevention resource allocation planning aimed provide estimate period 19902021 estimated incidence prevalence death disabilityadjusted lifeyear DALY count agestandardised rate per 100 000 people per year overall stroke ischaemic stroke intracerebral haemorrhage subarachnoid haemorrhage 204 country territory 1990 2021 also calculated burden stroke attributable 23 risk factor six risk cluster air pollution tobacco smoking behavioural dietary environmental metabolic risks global regional level 21 GBD region Sociodemographic Index SDI quintiles using standard GBD methodology 95 uncertainty interval UIs individual future estimate derived 2·5th 97·5th percentile distribution generated propagating 500 draw multistage computational pipeline 2021 stroke third common GBD level 3 cause death 7·3 million 95 UI 6·67·8 deaths 10·7 9·811·3 deaths ischaemic heart disease COVID19 fourth common cause DALYs 160·5 million 147·8171·6 DALYs 5·6 5·06·1 DALYs 2021 93·8 million 89·099·3 prevalent 11·9 million 10·713·2 incident strokes found disparity stroke burden risk factor GBD region country territory SDI well stagnation reduction incidence 2015 onwards even increase stroke incidence death prevalence DALY rate southeast Asia east Asia Oceania country lower SDI people younger 70 years Globally ischaemic stroke constituted 65·3 62·467·7 intracerebral haemorrhage constituted 28·8 28·328·8 subarachnoid haemorrhage constituted 5·8 5·76·0 incident strokes substantial increase DALYs attributable high BMI 88·2 53·4117·7 high ambient temperature 72·4 51·1 179·5 high fasting plasma glucose 32·1 26·738·1 diet high sugarsweetened beverage 23·4 12·735·7 low physical activity 11·3 1·834·9 high systolic blood pressure 6·7 2·511·6 lead exposure 6·5 4·511·2 diet low omega6 polyunsaturated fatty acid 5·3 0·510·5 Stroke burden increased 1990 2021 contribution several risk factor also increased Effective accessible affordable measure improve stroke surveillance prevention with emphasis blood pressure lifestyle environmental factors acute care rehabilitation need urgently implemented across country reduce stroke burden Bill  Melinda Gates Foundation",
        "mesh_terms": [
            "Humans",
            "Global Burden of Disease",
            "Risk Factors",
            "Stroke",
            "Global Health",
            "Disability-Adjusted Life Years",
            "Incidence",
            "Prevalence",
            "Quality-Adjusted Life Years",
            "Male",
            "Female"
        ],
        "source": "https://pubmed.ncbi.nlm.nih.gov/39304265/",
        "source_type": "Bangladesh-specific"
    },
    {
        "pmid": "38484753",
        "title": "Global age-sex-specific mortality, life expectancy, and population estimates in 204 countries and territories and 811 subnational locations, 1950-2021, and the impact of the COVID-19 pandemic: a comprehensive demographic analysis for the Global Burden of Disease Study 2021.",
        "abstract": "Estimates demographic metric crucial assess level trend population health outcomes profound impact COVID19 pandemic population worldwide underscored need timely estimate understand unprecedented event within context longterm population health trends Global Burden Diseases Injuries Risk Factors Study GBD 2021 provides new demographic estimate 204 country territory 811 additional subnational location 1950 2021 particular emphasis change mortality life expectancy occurred 202021 COVID19 pandemic period 22 223 data source vital registration sample registration surveys censuses source used estimate mortality subset source used exclusively estimate excess mortality due COVID19 pandemic 2026 data source used population estimation Additional source used estimate migration effect HIV epidemic demographic discontinuity due conflicts famines natural disasters pandemics used input estimating mortality population Spatiotemporal Gaussian process regression STGPR used generate under5 mortality rates synthesised 30 763 locationyears vital registration sample registration data 1365 survey censuses 80 sources STGPR also used estimate adult mortality between age 15 59 years based information 31 642 locationyears vital registration sample registration data 355 survey censuses 24 sources Estimates child adult mortality rate used generate life table relational model life table system country large HIV epidemics life table adjusted using independent estimate HIVspecific mortality generated via epidemiological analysis HIV prevalence surveys antenatal clinic serosurveillance data sources Excess mortality due COVID19 pandemic 2020 2021 determined subtracting observed allcause mortality adjusted late registration mortality anomalies mortality expected absence pandemic Expected mortality calculated based historical trend using ensemble models locationyears allcause mortality data unavailable estimated excess mortality rate using regression model covariates pertaining pandemic Population size computed using Bayesian hierarchical cohort component model Life expectancy calculated using agespecific mortality rate standard demographic methods Uncertainty interval UIs calculated every metric using 25th 975th ordered value 1000draw posterior distribution Global allcause mortality followed two distinct pattern study period agestandardised mortality rate declined 1950 2019 a 62·8 95 UI 60·565·1 decline increased COVID19 pandemic period 202021 5·1 0·99·6 increase contrast overall reverse mortality trend pandemic period child mortality continued decline 4·66 million 3·985·50 global death child younger 5 year 2021 compared 5·21 million 4·506·01 2019 estimated 131 million 126137 people died globally cause 2020 2021 combined 15·9 million 14·717·2 due COVID19 pandemic measured excess mortality includes death directly due SARSCoV2 infection indirectly due social economic behavioural change associated pandemic Excess mortality rate exceeded 150 death per 100 000 population least one year pandemic 80 country territories whereas 20 nation negative excess mortality rate 2020 2021 indicating allcause mortality country lower pandemic expected based historical trends 1950 2021 global life expectancy birth increased 22·7 year 20·824·8 49·0 year 46·751·3 71·7 year 70·972·5 Global life expectancy birth declined 1·6 year 1·02·2 2019 2021 reversing historical trends increase life expectancy observed 32 15·7 204 country territory 2019 2021 global population reached 7·89 billion 7·678·13 people 2021 time 56 204 country territory peaked subsequently population declined largest proportion population growth 2020 2021 subSaharan Africa 39·5 28·452·7 south Asia 26·3 9·044·7 2000 2021 ratio population aged 65 year older population aged younger 15 year increased 188 92·2 204 nations Global adult mortality rate markedly increased COVID19 pandemic 2020 2021 reversing past decreasing trends child mortality rate continued decline albeit slowly earlier years Although COVID19 substantial impact many demographic indicator first 2 year pandemic overall global health progress 72 year evaluated profound considerable improvement mortality life expectancy Additionally observed deceleration global population growth since 2017 despite steady increasing growth lowerincome countries combined continued global shift population age structure towards older ages demographic change likely present future challenge health systems economies societies comprehensive demographic estimate reported enable researchers policy makers health practitioners key stakeholder better understand address profound change occurred global health landscape following first 2 year COVID19 pandemic longerterm trend beyond pandemic Bill  Melinda Gates Foundation",
        "mesh_terms": [
            "Humans",
            "COVID-19",
            "Life Expectancy",
            "Global Burden of Disease",
            "Female",
            "Adult",
            "Male",
            "Adolescent",
            "Child",
            "Middle Aged",
            "Global Health",
            "Child, Preschool",
            "Infant",
            "Young Adult",
            "Aged",
            "SARS-CoV-2",
            "Mortality",
            "Infant, Newborn",
            "Demography",
            "Pandemics",
            "Aged, 80 and over",
            "Age Distribution"
        ],
        "source": "https://pubmed.ncbi.nlm.nih.gov/38484753/",
        "source_type": "Bangladesh-specific"
    },
    {
        "pmid": "38379753",
        "title": "A qualitative exploration of purchasing, stockpiling, and use of drugs during the COVID-19 pandemic in an urban city of Bangladesh.",
        "abstract": "research conducted explore pattern behavior panic purchasing stockpiling use drug COVID19 Sylhet city Bangladesh study adopted qualitative exploratory research design 25 indepth interview drug seller client 7 key informant interview conducted pharmacist medical representative pharmaceutical company Sylhet city Bangladesh October 2020 March 2021 Thematic analysis used evaluate primary data finding revealed individual sought out purchased stockpiled prescriptiononly drug selfmedication purpose COVID19 pandemic News rumor spread social media television everyday interaction concerning severity infection number death caused increase selfmedication preventive measure reason panic buying drug identified fear drug shortages price hikes rise infection availability medicine home delivery service pandemic purchasing stockpiling use drug pharmacy varied based person dispensing drugs customer COVID19 pandemic situation Furthermore role social medium spreading rumor dis misinformation drug use greater tendency selfmedicate poor regulation influenced individuals use drugs Therefore drug regulatory authority policymakers need consider real level local drug use order encourage rational use drug help ensure reliable access safe effective highquality medicine vaccine all",
        "mesh_terms": [],
        "source": "https://pubmed.ncbi.nlm.nih.gov/38379753/",
        "source_type": "Bangladesh-specific"
    },
    {
        "pmid": "38146969",
        "title": "Costs of Digital Adherence Technologies for Tuberculosis Treatment Support, 2018-2021.",
        "abstract": "Digital adherence technology increasingly used support tuberculosis TB treatment adherence Using microcosting estimated healthcare system cost in 2022 US dollars 2 digital adherence technologies 99DOTS medication sleeve videoobserved therapy VOT implemented demonstration project 20182021 also obtained cost estimate standard directly observed therapy DOT Estimated perperson cost 99DOTS drugsensitive TB 98 Bangladesh n  719 119 Philippines n  396 174 Tanzania n  976 Estimated perperson cost VOT 1154 Haiti 87 drugsensitive 304 Moldova 173 drugsensitive 452 Moldova 135 drugresistant 661 Philippines 110 drugresistant 99DOTS cost may similar less expensive standard DOT VOT expensive although settings labor cost offset economy scale may yield savings 99DOTS VOT may yield saving local program donor cover infrastructure costs",
        "mesh_terms": [
            "Humans",
            "Bangladesh",
            "Directly Observed Therapy",
            "Haiti",
            "Health Care Costs",
            "Income"
        ],
        "source": "https://pubmed.ncbi.nlm.nih.gov/38146969/",
        "source_type": "Bangladesh-specific"
    },
    {
        "pmid": "38123228",
        "title": "Safety and efficacy of primaquine in patients with <i>Plasmodium vivax</i> malaria from South Asia: a systematic review and individual patient data meta-analysis.",
        "abstract": "optimal dosing primaquine prevent relapsing iPlasmodium vivaxi malaria South Asia remains unclear investigated efficacy safety different primaquine regimen prevent iP vivaxi relapse systematic review identified iP vivaxi efficacy study South Asia published 1 January 2000 23 August 2021 onestage metaanalysis available individual patient data cumulative risk iP vivaxi recurrence day 42 180 assessed primaquine total mgkg dose duration risk recurrence day 180 also determined twostage metaanalysis Patients 25 drop haemoglobin 70 gL absolute drop 50 gL day 1 14 categorised daily mgkg primaquine dose 791 patient 7 study onestage metaanalysis day 180 cumulative risk recurrence 611 95 CI 422 804 201 patients 25 recurrences treatment without primaquine 288 95 CI 82 741 398 patients 4 recurrences following low total 2 5 mgkg 0 96 patients 0 recurrences following high total dose primaquine ≥5 mgkg subsequent twostage metaanalysis nine study 3529 patients pooled proportion iP vivaxi recurrence day 180 121 95 CI 77 172 23 95 CI 03 54 07 95 CI 0 61 respectively patient 25 drop haemoglobin 70 gL Primaquine treatment led marked decrease iP vivaxi recurrence following low 35 mgkg high 7 mgkg total doses reported severe haemolytic events CRD42022313730",
        "mesh_terms": [
            "Humans",
            "Primaquine",
            "Malaria, Vivax",
            "Antimalarials",
            "Plasmodium vivax",
            "Recurrence",
            "Asia, Southern",
            "Hemoglobins"
        ],
        "source": "https://pubmed.ncbi.nlm.nih.gov/38123228/",
        "source_type": "Bangladesh-specific"
    },
    {
        "pmid": "37979594",
        "title": "Primaquine radical cure in patients with Plasmodium falciparum malaria in areas co-endemic for P falciparum and Plasmodium vivax (PRIMA): a multicentre, open-label, superiority randomised controlled trial.",
        "abstract": "area coendemic Plasmodium vivax Plasmodium falciparum increased risk P vivax parasitaemia following P falciparum malaria Radical cure currently recommended patient presenting P vivax malaria Expanding indication radical cure patient presenting P falciparum malaria could reduce risk subsequent P vivax parasitaemia multicentre openlabel superiority randomised controlled trial five health clinic Bangladesh Indonesia Ethiopia Bangladesh Indonesia patient excluded younger 1 year whereas Ethiopia patient excluded younger 18 years Patients uncomplicated P falciparum monoinfection fever history fever 48 h preceding clinic visit eligible enrolment required glucose6dehydrogenase G6PD activity 70 greater Patients received blood schizontocidal treatment artemetherlumefantrine Ethiopia Bangladesh dihydroartemisininpiperaquine Indonesia randomly assigned 11 receive either highdose shortcourse oral primaquine intervention arm total dose 7 mgkg 7 days standard care standard care arm single dose oral primaquine 0·25 mgkg Random assignment done independent statistician block eight use sealed envelopes randomly assigned eligible patient included primary safety analyses perprotocol analysis excluded complete treatment substantial protocol violations primary endpoint incidence risk P vivax parasitaemia day 63 trial registered ClinicalTrialsgov NCT03916003 Aug 18 2019 March 14 2022 total 500 patient enrolled randomly assigned 495 eligible patient included intentiontotreat analysis 246 intervention 249 control incidence risk P vivax parasitaemia day 63 11·0 95 CI 7·515·9 standard care arm compared 2·5 1·05·9 intervention arm hazard ratio 0·20 95 CI 0·080·51 p0·0009 effect size differed blood schizontocidal treatment site Routine symptom reporting day 2 day 7 similar groups first 42 days total four primaquinerelated adverse event reported standard care arm 26 intervention arm 132 92 143 adverse event mild two serious adverse event intervention arm considered unrelated study drug None patient developed severe anaemia defined haemoglobin 5 gdL patient G6PD activity 70 greater highdose shortcourse primaquine safe relatively well tolerated reduced risk subsequent P vivax parasitaemia within 63 day five fold Universal radical cure therefore potentially offer substantial clinical public health operational benefits benefit vary endemic setting Australian Academy Science Regional Collaborations Program Bill  Melinda Gates Foundation National Health Medical Research Council",
        "mesh_terms": [
            "Humans",
            "Primaquine",
            "Antimalarials",
            "Plasmodium vivax",
            "Artemether",
            "Artemether, Lumefantrine Drug Combination",
            "Australia",
            "Malaria, Falciparum",
            "Malaria, Vivax",
            "Malaria",
            "Plasmodium falciparum",
            "Parasitemia"
        ],
        "source": "https://pubmed.ncbi.nlm.nih.gov/37979594/",
        "source_type": "Bangladesh-specific"
    },
    {
        "pmid": "37824592",
        "title": "Clinical performance validation of the STANDARD G6PD test: A multi-country pooled analysis.",
        "abstract": "Screening G6PD deficiency inform disease management including malaria Treatment antimalarial drug primaquine tafenoquine guided pointofcare testing G6PD deficiency Data similar clinical study evaluating performance STANDARD G6PD Test SD Biosensor South Korea conducted Bangladesh Brazil Ethiopia India Thailand United Kingdom United States pooled Test performance assessed retrospective analysis capillary venous specimens study site used spectrophotometry reference G6PD testing either HemoCue complete blood count reference hemoglobin measurement sensitivity STANDARD G6PD Test using manufacturer threshold G6PD deficient intermediate case capillary specimen 4212 study participant 100 95 Confidence Interval CI 975100 G6PD deficient case 30 activity 77 95 CI 668854 female intermediate activity 3070 Specificity 981 95 CI 976985 928 95 CI 916939 G6PD deficient individual intermediate females respectively 20 G6PD intermediate female false normal results 12 activity level 60 reference assay negative predictive value female G6PD activity 60 996 95 CI 991998 capillary specimens Sensitivity among 396 P vivax malaria case 100 6921000 deficient intermediate cases Across full dataset 37 classified G6PD deficient intermediate resulted true normal cases Despite this 95 case would receive correct treatment primaquine 87 case would receive correct treatment tafenoquine true G6PD deficient case would treated inappropriately based result STANDARD G6PD Test STANDARD G6PD Test enables safe access drug contraindicated individual G6PD deficiency Operational consideration inform test uptake specific settings",
        "mesh_terms": [
            "Female",
            "Humans",
            "Primaquine",
            "Glucosephosphate Dehydrogenase Deficiency",
            "Retrospective Studies",
            "Antimalarials",
            "Malaria, Vivax"
        ],
        "source": "https://pubmed.ncbi.nlm.nih.gov/37824592/",
        "source_type": "Bangladesh-specific"
    },
    {
        "pmid": "37646297",
        "title": "Pharmaco-disparities in heart failure: a survey of the affordability of guideline recommended therapy in 10 countries.",
        "abstract": "Heart failure reduced ejection fraction HFrEF treatable guidelinedirected medical therapy GDMT may affordable accessible people living disease crosssectional survey investigated price affordability accessibility four pivotal class HFrEF GDMT angiotensinconverting enzyme inhibitor ACEi angiotensin receptor blocker ARB angiotensinneprilysin inhibitor ARNI betablockers mineralocorticoid receptor antagonist MRA sodium glucose cotransporter 2 inhibitor SGLT2i sampled online community pharmacy 10 country across range World Bank income groups assessing mean 30 day retail prescription prices affordability relative gross national income per caput per month accessibility reported median price ratio relative International Reference Standard performed literature review evaluate accessibility GDMT class publicly funded drug programme country HFrEF GDMT prices absolute relative international reference highest United States lowest Pakistan Bangladesh expensive drug ARNI sacubitrilvalsartan mean standard deviation SD 30 day price ranging 1106 081 Pakistan 61150 354 United States least expensive drug MRA spironolactone mean SD 30 day price ranging 018 000 Pakistan 1232 000 England Affordability SD quadruple therapyARNI betablockers MRA SGLT2iwas best highincome worst lowincome countries ranging 149 000 gross national income per caput per month England 23247 3147 Uganda Publicly funded drug programme offset cost eligible patients ARNI SGLT2i inaccessible programme low middleincome countries Price affordability access substantially improved country substituting ARNI ACEiARB marked variation country retail price HFrEF GDMT Despite higher price highincome countries GDMT accessible affordable low middleincome countries Publicly funded drug programme lower income country increased affordability limited access newer HFrEF GDMT classes Pharmacodisparities must addressed improve HFrEF outcome globally",
        "mesh_terms": [
            "Humans",
            "Heart Failure",
            "Cross-Sectional Studies",
            "Practice Guidelines as Topic",
            "Global Health",
            "Surveys and Questionnaires",
            "Health Services Accessibility",
            "Angiotensin Receptor Antagonists"
        ],
        "source": "https://pubmed.ncbi.nlm.nih.gov/37646297/",
        "source_type": "Bangladesh-specific"
    },
    {
        "pmid": "37379283",
        "title": "The reality of embedded drug purchasing practices: Understanding the sociocultural and economic aspects of the use of medicines in Bangladesh.",
        "abstract": "Purchasing drug without prescription retail drug shop common practice Bangladesh However actually take place drug seller customer transaction underresearched study explores drug purchasing practice underlie sociocultural economic aspect Bangladeshi city Adopting ethnographic methods conducted thirty indepth interview IDIs customers patients sale assistants ten key informant interview KIIs drug sellers experienced sale assistant pharmaceutical company representatives Thirty hour spent observing drug sellers buyers conversation interaction medicine total 40 heterogeneous participant purposively selected three drug stores Transcribed data coded analyzed thematically found thematic analysis individual visited drug store fixed idea name brand dose drug wanted Among 30 IDIs participants individual come without preconceived ideas describe symptoms negotiate purchase expectation quick remedies Cultural practice buying medicine full partial course doses without prescription trust sellers positive previous experience medication shape drug purchasing behavior regardless preconceived idea concerning brand name dose customer n  7 sought drug trade name drug seller often offered generic substitute selling nonbrand drug profitable Notably many client n  13 bought drug installment payment loans Community people choose purchase necessary medicine selfmedicated way shortly trained drug seller harm individuals health reduce effectiveness medication addition result buying medicine installment loan suggest research financial burden consumers purchasing behavior Policymakers regulators healthcare professional might implicate study finding deliver practical information rational use medicine seller customers",
        "mesh_terms": [
            "Humans",
            "Bangladesh",
            "Prescriptions",
            "Consumer Behavior",
            "Health Personnel",
            "Commerce"
        ],
        "source": "https://pubmed.ncbi.nlm.nih.gov/37379283/",
        "source_type": "Bangladesh-specific"
    },
    {
        "pmid": "37319165",
        "title": "Assessing the critical success factors for implementing industry 4.0 in the pharmaceutical industry: Implications for supply chain sustainability in emerging economies.",
        "abstract": "emerging technology Industry 40 I40 crucial incorporating agility sustainability smartness competitiveness business model enabling longterm sustainability practice pharmaceutical supply chain PSC leveraging latest technology I40 pharmaceutical company gain realtime visibility supply chain SC operations allowing make datadriven decision improve SC performance efficiency resilience sustainability However date research examined critical success factor CSFs enable pharmaceutical industry adopt I40 successfully enhance overall SC sustainability study therefore analyzed potential CSFs adopting I40 increase facet sustainability PSC especially perspective emerging economy like Bangladesh Initially sixteen CSFs identified comprehensive literature review expert validation Later finalized CSFs clustered three relevant group analyzed using Bayesian bestworst method BWMbased multicriteria decisionmaking MCDM framework study finding revealed sufficient investment technological advancement digitalized product monitoring traceability dedicated robust research development RD team top three CSFs adopt I40 PSC studys finding aid industrial practitioners managers policymakers creating effective action plan efficiently adopting I40 PSC avail competitive benefit ensure sustainable future pharmaceutical industry",
        "mesh_terms": [
            "Bayes Theorem",
            "Commerce",
            "Drug Industry",
            "Investments",
            "Pharmaceutical Preparations"
        ],
        "source": "https://pubmed.ncbi.nlm.nih.gov/37319165/",
        "source_type": "Bangladesh-specific"
    },
    {
        "pmid": "37243851",
        "title": "Affordability of newer antiseizure medications in Asian resource-limited countries.",
        "abstract": "One objective Intersectoral Global Action Plan epilepsy neurological disorder 2022 2031 ensure least 80 people epilepsy PWE access appropriate affordable safe antiseizure medication ASMs 2031 However ASM affordability significant issue low middleincome countries preventing PWE accessing optimal treatment study aimed determine affordability newer second third generation ASMs resourcelimited country Asia conducted crosssectional survey contacting country representative lowermiddleincome country LMICs Asia including Indonesia Lao Peoples Democratic Republic PDR Myanmar Philippines Vietnam India Bangladesh Pakistan uppermiddleincome country Malaysia March 2022 April 2022 affordability ASM calculated dividing 30day ASM cost daily wage lowest paid unskilled laborers Treatment costing 1 days wage less 30day supply chronic disease considered affordable Eight LMICs one uppermiddleincome country included study Lao PDR newer ASM Vietnam three newer ASMs frequently available ASMs levetiracetam topiramate lamotrigine least frequently available lacosamide majority newer ASMs unaffordable median number days wage 30day supply ranging 56 148 days new generation ASMs whether original generic brands unaffordable Asian LMICs",
        "mesh_terms": [
            "Humans",
            "Cross-Sectional Studies",
            "Asia",
            "India",
            "Anticonvulsants",
            "Epilepsy",
            "Costs and Cost Analysis"
        ],
        "source": "https://pubmed.ncbi.nlm.nih.gov/37243851/",
        "source_type": "Bangladesh-specific"
    },
    {
        "pmid": "37076740",
        "title": "Optimal Interruption of P. vivax Malaria Transmission Using Mass Drug Administration.",
        "abstract": "Plasmodium vivax geographically widespread malariacausing parasite resulting significant associated global morbidity mortality One factor driving widespread phenomenon ability parasite remain dormant liver Known hypnozoites reside liver following initial exposure activating later cause infections referred relapses around 7996 infection attributed relapse activating hypnozoites expect highly impactful apply treatment target hypnozoite reservoir ie collection dormant parasites eliminate P vivax Treatment radical cure example tafenoquine primaquine target hypnozoite reservoir potential tool control andor eliminate P vivax developed deterministic multiscale mathematical model system integrodifferential equation capture complex dynamic P vivax hypnozoites effect hypnozoite relapse disease transmission Here use multiscale model study anticipated effect radical cure treatment administered via mass drug administration MDA program implement multiple round MDA fixed interval rounds starting different steadystate disease prevalences construct optimisation model three different objective function motivated public health basis obtain optimal MDA interval also incorporate mosquito seasonality model study effect optimal treatment regime find effect MDA intervention temporary depends preintervention disease prevalence and choice model parameters well number MDA round consideration optimal interval MDA round also depends objective combinations expected intervention outcomes find radical cure alone may enough lead P vivax elimination mathematical model and choice model parameters since prevalence infection eventually return preMDA levels",
        "mesh_terms": [
            "Animals",
            "Humans",
            "Malaria, Vivax",
            "Antimalarials",
            "Mass Drug Administration",
            "Models, Biological",
            "Mathematical Concepts",
            "Malaria",
            "Recurrence"
        ],
        "source": "https://pubmed.ncbi.nlm.nih.gov/37076740/",
        "source_type": "Bangladesh-specific"
    },
    {
        "pmid": "36931291",
        "title": "International manufacturing and trade in colistin, its implications in colistin resistance and One Health global policies: a microbiological, economic, and anthropological study.",
        "abstract": "emergence colistinresistant Enterobacterales global public health concern yet colistin still widely used animal used food treatment metaphylaxis prophylaxis growth promotion Herein investigate effect colistinresistant Enterobacterales Pakistan global trade colistin colistin use farm level relevant socioeconomic factors conducted microbiological economic anthropological study colistinresistant Escherichia coli humans animals environment international trade knowledge colistin Pakistan Bangladesh Nigeria China India Viet Nam collected backyard poultry cloacal swabs commercial broiler cloacal swabs cattle buffalo rectal swabs human rectal swabs wild bird droppings cattle buffalo meat sewage water poultry flies chicken meat canal water 131 site across Faisalabad Pakistan tested mcr1positive mcr3positive Escherichia coli recruited new patient admitted Allied Hospital Faisalabad Pakistan abdominal pain diarrhoea rectal swabs Patients dysentery already antibiotic treatment excluded Data colistin trade 2017 2020 including importation manufacturing usage accessed online database government source Pakistan Bangladesh Nigeria recruited participant poultry farm veterinary drug store Pakistan Nigeria interviewed using structured questionnaire International manufacturing import export data value analysis trade route colistin pharmaceutical raw material PRM feed additive finished pharmaceutical product FPPs accessed 201721 export data sets collected 1131 sample May 12 2018 July 1 2019 backyard poultry cloacal swab n100 commercial broiler cloacal swab n102 cattle buffalo rectal swab n188 human rectal swab n200 wild bird droppings n100 cattle buffalo meat n100 sewage water n90 poultry fly n100 chicken meat n100 canal water n51 recruited 200 inpatient Allied Hospital Faisalabad Pakistan Nov 15 2018 Dec 14 2018 rectal swabs recruited 21 participant Jan 1 2020 Dec 31 2020 poultry farm drug store Pakistan Nigeria interviewed 75 7 1131 sample contained mcr1positive E coli including wild bird droppings 25 25 100 commercial broiler cloacal swab 17 17 100 backyard poultry cloacal swab one 1 100 chicken meat 13 13 100 cattle buffalo meat two 2 100 poultry fly eight 8 100 sewage water six 7 90 human rectal swab three 2 200 201720 Pakistan imported 275·5 tonne 68·9 tonne per year 95 CI 41·296·6 colistin PRM sourced China 701·9 tonne 175·5 tonne per year 140·9210·1 colistin feed additive China Viet Nam 63·0 tonne 15·8 tonne per year 10·421·1 colistin FPPs various country Asia Europe Bangladesh Nigeria colistin PRM FPPs imported China Europe Colistin knowledge usage practice Pakistan Nigeria unsatisfactory term understanding effect human medicine usage treatment purposes China major manufacturer PRM feed additive colistin exported total 2664·8 tonne 666·2 tonne per year 95 CI 262·1 1070·2 PRM 2570·2 tonne 642·6 tonne per year 89·4 1374·5 feed additive 1330 shipment 201821 21 countries Regardless 193 country signing UN agreement tackle antimicrobial resistance trading colistin PRM FPPs feed additive growth promoter lowincome middleincome country continues unabated Robust national international law urgently required mitigate international trade antimicrobial listed Critically Important Antimicrobials Human Medicine Pakistan Agricultural Research Council INEOS Oxford Institute Antimicrobial Research TRANSLATION Urdu translation abstract see Supplementary Materials section",
        "mesh_terms": [
            "Cattle",
            "Animals",
            "Humans",
            "Colistin",
            "Escherichia coli",
            "Sewage",
            "Buffaloes",
            "Commerce",
            "One Health",
            "Chickens",
            "Internationality",
            "Poultry",
            "Anti-Infective Agents",
            "Policy",
            "Pakistan",
            "Escherichia coli Proteins"
        ],
        "source": "https://pubmed.ncbi.nlm.nih.gov/36931291/",
        "source_type": "Bangladesh-specific"
    },
    {
        "pmid": "36864926",
        "title": "Pf7: an open dataset of <i>Plasmodium falciparum</i> genome variation in 20,000 worldwide samples.",
        "abstract": "describe MalariaGEN Pf7 data resource seventh release iPlasmodium falciparumi genome variation data MalariaGEN network comprises 20000 sample 82 partner study 33 countries including several malaria endemic region previously underrepresented first time include dried blood spot sample sequenced selective whole genome amplification necessitating new method genotype copy number variations identify large number newly emerging icrti mutation part Southeast Asia show example heterogeneity pattern drug resistance within Africa within Indian subcontinent describe profile variation Cterminal icspi gene relate sequence used RTSS R21 malaria vaccines Pf7 provides highquality data genotype call 6 million SNPs short indels analysis large deletion cause failure rapid diagnostic tests systematic characterisation six major drug resistance loci freely downloaded MalariaGEN website",
        "mesh_terms": [],
        "source": "https://pubmed.ncbi.nlm.nih.gov/36864926/",
        "source_type": "Bangladesh-specific"
    },
    {
        "pmid": "36813535",
        "title": "Olanzapine cost-effectiveness in vomiting and nausea from highly emetogenic chemotherapy in children and adolescents.",
        "abstract": "assess costeffectiveness addition olanzapine prophylactic antiemetic regimen containing aprepitant dexamethasone ondansetron among child receiving highly emetogenic chemotherapy HEC India Bangladesh Indonesia UK USA Health state estimated using individual patientlevel outcome data randomised trial incremental costutility ratio ICUR incremental costeffectiveness ratio net monetary benefit NMB calculated patient perspective India Bangladesh Indonesia UK USA Oneway sensitivity analysis done varying cost olanzapine cost hospitalisation utility value ±25 olanzapine arm increment 00018 qualityadjusted lifeyears QALY control arm mean total expenditure olanzapine arm greater US051 US043 US673 US1105 US1235 India Bangladesh Indonesia UK USA respectively ICURQALY US28260 India US24142 Bangladesh US375593 Indonesia US616183 UK US688741 USA NMB US986 US1012 US1408 US4474 US9879 India Bangladesh Indonesia UK USA respectively ICUR estimate base case sensitivity analysis willingnesstopay threshold scenarios addition olanzapine fourth agent antiemetic prophylaxis costeffective despite increase overall expenditure Olanzapine uniformly considered child receiving HEC",
        "mesh_terms": [
            "Adolescent",
            "Child",
            "Humans",
            "Antiemetics",
            "Antineoplastic Agents",
            "Cost-Benefit Analysis",
            "Dexamethasone",
            "Nausea",
            "Olanzapine",
            "Vomiting",
            "Randomized Controlled Trials as Topic"
        ],
        "source": "https://pubmed.ncbi.nlm.nih.gov/36813535/",
        "source_type": "Bangladesh-specific"
    },
    {
        "pmid": "36782190",
        "title": "Comparison of simplicity, convenience, safety, and cost-effectiveness between use of insulin pen devices and disposable plastic syringes by patients with type 2 diabetes mellitus: a cross-sectional study from Bangladesh.",
        "abstract": "Insulin pen device disposable plastic insulin syrinx two common tool insulin administration study aim compare simplicity convenience safety costeffectiveness insulin pen versus syringe device patient type 2 diabetes mellitus T2DM crosssectional study conducted 14 diabetes clinic throughout Bangladesh November 2021 April 2022 among adult T2DM injecting insulin pen device disposable insulin syrinx least day least one year purposive sampling simplicity convenience safety insulin device assessed using structured questionnaire study subject scored based answers higher score indicated poorer response Total score simplicity convenience safety obtained adding score relevant components average monthly medical expense cost insulin therapy recorded median value total score monthly expense compared pen device disposable syringe users 737 subject evaluated 406 pen users 331 vial syringe users pen user lower median score simplicity 60 5080 vs 70 5090 p  0002 convenience 40 3060 vs 50 4060 p  0001 safety 70 6080 vs 70 6090 p  0008 vial syringe users Pen device expensive vial syrinx term average medical expense per month BDT 5000 35007000 vs 3000 20005000 p  0001 total cost insulin therapy per month BDT 2000 15003000 vs 1200 8001700 p  0001 cost per unit insulin used BDT 208 139278 vs 096 064139 p  0001 Nonsignificant difference favor pen observed HbA1c level 87 7810 vs 89 7910 p  0607 proportion subject HbA1c  7 69 vs 63 p  0991 Insulin pen simpler convenient safe expensive vial syringes Glycemic control comparable pen syringe users Longterm followup study needed determine clinical economic impact benefit insulin pens",
        "mesh_terms": [
            "Adult",
            "Humans",
            "Bangladesh",
            "Cost-Benefit Analysis",
            "Cross-Sectional Studies",
            "Diabetes Mellitus, Type 2",
            "Disposable Equipment",
            "Glycated Hemoglobin",
            "Hypoglycemic Agents",
            "Insulin",
            "Retrospective Studies",
            "Syringes",
            "Drug Delivery Systems"
        ],
        "source": "https://pubmed.ncbi.nlm.nih.gov/36782190/",
        "source_type": "Bangladesh-specific"
    },
    {
        "pmid": "36545347",
        "title": "Cost of oral cholera vaccine delivery in a mass immunization program for children in urban Bangladesh.",
        "abstract": "Cholera pose substantial health burden developing world due epidemic endemic diseases World Health Organization recommends oral cholera vaccine mass vaccination campaign addition traditional prevention practice treatment resourcepoor settings many developing country like Bangladesh major challenge behind implementing mass vaccination campaign concern affordability oral cholera vaccine OCV Vaccination child OCV impactful approach controlling cholera population level reducing childhood morbidity also considered costeffective vaccinating ages aim study estimate cost OCV campaign child societal perspective using empirical study total 66311 child aged 1 14 year old fully vaccinated two dos OCV Shanchol 9035 individual received one dose vaccine estimated societal cost per individual full vaccination US 611 includes cost vaccine delivery estimated US 195 cost per single dose estimated US 286 total provider cost full vaccination estimated US 601 recipient cost US 010 estimation OCV delivery cost child relatively higher found similar mass OCV campaign age groups indicating may additional cost factor consider targeted vaccine campaigns analysis provides useful benchmark possible cost related delivery OCV child future OCV costeffectiveness model factor possible cost disparities Attempts reduce cost per dose likely greater impact cost similar vaccination campaign many resourcepoor settings",
        "mesh_terms": [],
        "source": "https://pubmed.ncbi.nlm.nih.gov/36545347/",
        "source_type": "Bangladesh-specific"
    },
    {
        "pmid": "36192508",
        "title": "Cost-effectiveness of universal iron supplementation and iron-containing micronutrient powders for anemia among young children in rural Bangladesh: analysis of a randomized, placebo-controlled trial.",
        "abstract": "Universal provision iron supplement ironcontaining multiple micronutrient powder MNPs widely used prevent anemia young child low middleincome countries BRISC Benefits Risks Iron Interventions Children trial compared iron supplement MNPs placebo child 2 old rural Bangladesh aimed assess costeffectiveness iron supplement ironcontaining MNPs among young child rural Bangladesh costeffectiveness analysis MNPs iron supplement using BRISC trial outcome resource use data programmatic data literature Health care cost assessed health system perspective calculated incremental costeffectiveness ratio ICERs term US per disabilityadjusted lifeyear DALY averted explore uncertainty constructed costeffectiveness acceptability curve using bootstrapped data range costeffectiveness thresholds One 2way sensitivity analysis tested impact varying key parameter value results Provision MNPs estimated avert 00031 95 CI 00022 00041 DALYschild whereas iron supplement averted 00039 95 CI 00030 00048 DALYschild 1 compared intervention Incremental mean cost 075 95 CI 073 077 MNPs compared intervention 064 062 067 iron supplement compared intervention Iron supplementation dominated MNPs cheaper averted DALYs Iron supplementation ICER 1645 1333 2153 per DALY averted compared intervention 0 probability optimal strategy costeffectiveness threshold 200 reflecting health opportunity cost Bangladesh 985 half gross domestic product GDP per capita per DALY averted Scenario sensitivity analysis supported base case findings finding support universal iron supplementation micronutrient powder costeffective intervention young child rural Bangladesh trial registered anzctrorgau ACTRN1261700066038 trialsearchwhoint U111111961125",
        "mesh_terms": [
            "Child",
            "Humans",
            "Child, Preschool",
            "Iron",
            "Micronutrients",
            "Cost-Benefit Analysis",
            "Powders",
            "Bangladesh",
            "Dietary Supplements",
            "Trace Elements",
            "Anemia"
        ],
        "source": "https://pubmed.ncbi.nlm.nih.gov/36192508/",
        "source_type": "Bangladesh-specific"
    },
    {
        "pmid": "36182233",
        "title": "Economic loss attributable to cigarette smoking in the USA: an economic modelling study.",
        "abstract": "Despite large geographical disparity prevalence cigarette smoking across USA paucity statelevel estimate economic loss attributable smoking inform tobacco control policy national state levels aimed estimate statelevel economic loss attributable cigarette smoking USA economic modelling study used dynamic macroeconomic model personal income per caput state level Based publicly available data statelevel income determinants smoking status 201120 first estimated elasticity personal income per caput respect prevalence nonsmoking adult aged ≥18 years USA using mixedeffects generalised linear dynamic panel data model used estimated elasticity measure statespecific annual avoidable economic loss attributable cigarette smoking 2020 counterfactual 5 prevalence cigarette smoking estimated statespecific cumulative economic loss attributable cigarette smoking 2020 using coefficient lagged income dynamic model National estimate economic loss attributable cigarette smoking obtained summing statespecific estimates mixedeffects model elasticity personal income per caput respect prevalence nonsmoking adult 0·143 p0·063 estimated annual income loss per caput 2020 ranged US331 Utah 1674 Kentucky state mean populationweighted loss per caput 1100 annual combined loss income unpaid household production national level 436·7 billion equivalent 2·1 US gross domestic product GDP 2020 cumulative loss income unpaid household production 864·5 billion equivalent 4·3 US GDP 2020 Smoking cause substantial economic loss USA Tobacco control effort lower prevalence smoking equitably contribute considerably improved macroeconomic performance short long term reducing health expenditure avoiding productivity losses American Cancer Society",
        "mesh_terms": [
            "Adolescent",
            "Adult",
            "Cigarette Smoking",
            "Health Expenditures",
            "Humans",
            "Models, Economic",
            "Tobacco Products",
            "United States"
        ],
        "source": "https://pubmed.ncbi.nlm.nih.gov/36182233/",
        "source_type": "Bangladesh-specific"
    },
    {
        "pmid": "36145477",
        "title": "Genetic Variants of Glucose-6-Phosphate Dehydrogenase and Their Associated Enzyme Activity: A Systematic Review and Meta-Analysis.",
        "abstract": "Low glucose6phosphate dehydrogenase enzyme G6PD activity key determinant druginduced haemolysis 230 clinically relevant genetic variant described investigated variation G6PD activity within different genetic variants systematic review individual patient data study reporting G6PD activity measured spectrophotometry corresponding G6PD genotype pooled PROSPERO CRD42020207448 G6PD activity converted percent normal activity applying studyspecific definition 100 total 4320 individual 17 study across 10 country included 1738 402 one 24 confirmed G6PD mutations 61 observation 35 identified outliers median activity hemihomozygotes Ac202GAc376AG 290 range 17 766 102 range 00 325 Mahidol 169 range 33 213 Mediterranean 90 range 29 232 Vanua Lava 75 range 00 183 Viangchan median activity heterozygote 721 range 164 1271 Ac202GAc376AG 545 range 00 1128 Mahidol 379 range 207 805 Mediterranean 538 range 109 825 Vanua Lava 523 range 48 786 Viangchan total 995 hemihomozygotes Mahidol mutation 100 Mediterranean Vanua Lava Viangchan mutation 30 activity Ac202GAc376AG 55 hemihomozygotes 30 activity G6PD activity variant spanned current classification threshold used define clinically relevant category enzymatic deficiency",
        "mesh_terms": [],
        "source": "https://pubmed.ncbi.nlm.nih.gov/36145477/",
        "source_type": "Bangladesh-specific"
    },
    {
        "pmid": "36109733",
        "title": "Safety of single-dose primaquine as a Plasmodium falciparum gametocytocide: a systematic review and meta-analysis of individual patient data.",
        "abstract": "2012 World Health Organization WHO recommended single lowdose SLD 025 mgkg primaquine added Plasmodium P falciparum gametocytocide artemisininbased combination therapy ACT without glucose6phosphate dehydrogenase G6PD testing accelerate malaria elimination effort avoid spread artemisinin resistance Uptake recommendation relatively slow primarily due safety concerns systematic review individual patient data IPD metaanalysis singledose SD primaquine study P falciparum malaria performed Absolute fractional change haemoglobin concentration within week adverse effect within 28 day treatment initiation characterised compared primaquine primaquine arm using random intercept models Data comprised 20 study enrolled 6406 participants 5129 801 received single target dose primaquine ranging 00625 075 mgkg effect primaquine G6PDnormal participant haemoglobin concentrations However among 194 G6PDdeficient African participants 025 mgkg primaquine target dose resulted additional 053 gdL 95 CI 017089 reduction haemoglobin concentration day 7 027 95 CI 019034 gdL haemoglobin drop estimated every 01 mgkg increase primaquine dose Baseline haemoglobin young age hyperparasitaemia main determinant becoming anaemic Hb  10 gdL nadir observed ACT day 2 3 regardless G6PD status exposure primaquine Time recovery anaemia took longer young child baseline anaemia hyperparasitaemia Serious adverse haematological event primaquine 93 113 03 transitory One blood transfusion reported primaquine arms primaquinerelated deaths controlled studies proportion either haematological serious adverse event similar primaquine primaquine arms result support recommendation use 025 mgkg primaquine P falciparum gametocytocide including G6PDdeficient individuals Although primaquine associated transient reduction haemoglobin level G6PDdeficient individuals haemoglobin level clinical presentation major determinant anaemia patients PROSPERO CRD42019128185",
        "mesh_terms": [
            "Antimalarials",
            "Artemisinins",
            "Child",
            "Child, Preschool",
            "Glucosephosphate Dehydrogenase",
            "Hemoglobins",
            "Humans",
            "Malaria, Falciparum",
            "Plasmodium falciparum",
            "Primaquine"
        ],
        "source": "https://pubmed.ncbi.nlm.nih.gov/36109733/",
        "source_type": "Bangladesh-specific"
    },
    {
        "pmid": "35840634",
        "title": "Antioxidant, cytotoxic and apoptotic activities of the rhizome of Zingiber zerumbet Linn. in Ehrlich ascites carcinoma bearing Swiss albino mice.",
        "abstract": "Due long history traditional us functional food Zingiber zerumbet selected explore inherent antioxidant antineoplastic activity methanolic extract rhizome MEZZR Ehrlich ascites carcinoma EAC cells rich polyphenol containing MEZZR showed marked DPPH ABTS nitric oxide radical lipid peroxidation inhibition activity ICsub50sub 343 ± 125 1138 ± 139 2312 ± 339 1647 ± 147 µgml respectively compared standard catechin vivo MEZZR significantly inhibited EAC cell growth decreased body weight gain increased life span restored altered hematological characteristic EACbearing mice Moreover MEZZR induced nuclear condensation fragmentation notable feature apoptosis observed fluorescence microscopy staining EAC cell MEZZRtreated mouse Hoechst 33342 Additionally vitro cell growth inhibition caused MEZZR MTT assay remarkably decreased presence caspase3 8 9 inhibitors study thus suggests MEZZR may possess promising antiproliferative efficacy EAC cell inducing cell apoptosis",
        "mesh_terms": [
            "Animals",
            "Antineoplastic Agents",
            "Antineoplastic Agents, Phytogenic",
            "Antioxidants",
            "Ascites",
            "Carcinoma, Ehrlich Tumor",
            "Mice",
            "Plant Extracts",
            "Rhizome"
        ],
        "source": "https://pubmed.ncbi.nlm.nih.gov/35840634/",
        "source_type": "Bangladesh-specific"
    },
    {
        "pmid": "35710474",
        "title": "The private sector market for malaria rapid diagnostic tests in Nigeria: results of the 2018 market survey.",
        "abstract": "avoid misuse antimalarials correct diagnosis fever prior drug prescription essential Presumptive treatment private healthcare sector concern Nigeria availability affordable artemisininbased combination therapy ACT high following implementation subsidy scheme 2010 2017 Similar subsidy not however implemented malaria rapid diagnostic test RDTs market survey 2018 predominantly designed assess ACT market private sector also collected data related RDTs result presented herein 2018 market survey consisted i outlet survey targeting private pharmacy Proprietary Patent Medicine Vendors PPMVs across different region Nigeria assess supplyside market factor related availability RDTs defined stock available purchase time survey ii household survey determine demandside factor related knowledge RDTs healthcareseeking practice affordability Availability RDTs time survey low outlet type significantly lower PPMVs 221 95 CI among pharmacy versus 136 95 CI among PPMVs p  001 Reasons restocking RDTs included low demand supply majority household diagnose malaria based experience onethird would visit PPMV pharmacy Half household heard RDTs 484 386 thought affordable Low availability RDTs among PPMVs pharmacy may attributed lack demand supplyside issue cost Increasing household knowledge RDTs may aid increasing demand subsidized RDTs may address supply price issues Addressing deficit RDT provision important targeting ACT medicines",
        "mesh_terms": [
            "Antimalarials",
            "Cross-Sectional Studies",
            "Diagnostic Tests, Routine",
            "Humans",
            "Malaria",
            "Nigeria",
            "Private Sector",
            "Surveys and Questionnaires"
        ],
        "source": "https://pubmed.ncbi.nlm.nih.gov/35710474/",
        "source_type": "Bangladesh-specific"
    },
    {
        "pmid": "35651694",
        "title": "An open dataset of <i>Plasmodium vivax</i> genome variation in 1,895 worldwide samples.",
        "abstract": "report describes MalariaGEN Pv4 dataset new release curated genome variation data 1895 sample iPlasmodium vivaxi collected 88 worldwide location 2001 2017 includes 1370 new sample contributed MalariaGEN VivaxGEN partner study addition previously published sample sources provide genotype call 45 million variable position including 3 million single nucleotide polymorphism SNPs well short indels tandem duplications enlarged dataset highlight major compartment parasite population structure clear differentiation Africa Latin America Oceania Western Asia different part Southeast Asia sample classified drug resistance sulfadoxine pyrimethamine mefloquine based known marker idhfri idhpsi imdr1i loci prevalence resistance marker much higher Southeast Asia Oceania elsewhere open resource analysisready genome variation data MalariaGEN VivaxGEN network driven collective goal advance research complex biology iP vivaxi accelerate genomic surveillance malaria control elimination",
        "mesh_terms": [],
        "source": "https://pubmed.ncbi.nlm.nih.gov/35651694/",
        "source_type": "Bangladesh-specific"
    },
    {
        "pmid": "35585641",
        "title": "Reducing the risk of Plasmodium vivax after falciparum infections in co-endemic areas-a randomized controlled trial (PRIMA).",
        "abstract": "Plasmodium vivax form dormant liver stage reactivate week month following acute infection Recurrent infection often associated febrile illness cause cumulative risk severe anaemia direct indirect mortality onward transmission parasite increased risk P vivax parasitaemia following falciparum malaria suggesting rationale universal use radically curative treatment patient P falciparum malaria even absence detectable P vivax parasitaemia area coendemic species multicentre health care facilitybased randomized controlled openlabel trial Bangladesh Indonesia Ethiopia Patients uncomplicated falciparum malaria G6PD activity ≥70 adjusted male median AMM haemoglobin level ≥8gdl recruited study randomized either receive standard schizonticidal treatment plus 7day high dose primaquine total dose 7mgkg standard care 11 ratio Patients followed weekly day 63 primary endpoint incidence risk P vivax parasitemia day 63 Secondary endpoint include incidence risk day 63 symptomatic P vivax malaria risk P falciparum parasitaemia Secondary safety outcome include proportion adverse event serious adverse events incidence risk severe anaemia Hb5gdl 7gdl andor risk blood transfusion incidence risk ≥ 25 fall haemoglobin without haemoglobinuria incidence risk ≥ 25 fall haemoglobin 7gdl without haemoglobinuria study evaluates potential benefit universal radical cure P vivax P falciparum different endemic locations found safe effective universal radical cure could represent costeffective approach clear otherwise unrecognised P vivax infection hence accelerate P vivax elimination NCT03916003  Registered 12 April 2019",
        "mesh_terms": [
            "Antimalarials",
            "Hemoglobinuria",
            "Humans",
            "Malaria",
            "Malaria, Falciparum",
            "Malaria, Vivax",
            "Male",
            "Plasmodium falciparum",
            "Plasmodium vivax",
            "Primaquine"
        ],
        "source": "https://pubmed.ncbi.nlm.nih.gov/35585641/",
        "source_type": "Bangladesh-specific"
    },
    {
        "pmid": "35544453",
        "title": "Variation in Glucose-6-Phosphate Dehydrogenase activity following acute malaria.",
        "abstract": "Primaquine tafenoquine licensed drug activity Plasmodium vivax hypnozoites cause haemolysis patient glucose6phosphate dehydrogenase G6PD deficiency Malaria also cause haemolysis leading replacement older erythrocyte low G6PD activity reticulocyte young erythrocyte higher activity Aim study assess impact acute malaria G6PD activity Selected patient uncomplicated malaria recruited Bangladesh n  87 Indonesia n  75 Ethiopia n  173 G6PD activity measured initial presentation malaria median 176 day later range 140 998 absence malaria Among selected participant deficient participant preferentially enrolled Bangladesh sites G6PD activity fell malaria follow 791 95CI 404 1178 6 participant classified deficient 30 activity 437 95CI 342 531 39 individual intermediate activity 30 70 45 95CI 14 76 290 G6PD normal ≥70 participants Bangladesh Indonesia G6PD activity significantly higher acute malaria individual retested follow 409 95CI 334481 74 95CI 02 146 respectively whereas Ethiopia G6PD activity 36 95CI 10 61 lower acute malaria change G6PD activity apparent patient presenting either P vivax P falciparum infection Overall 667 46 severely deficient participant 872 3439 intermediate deficiency normal activity presenting malaria finding suggest G6PD activity rise significantly clinically relevant level acute malaria Prospective casecontrol study warranted confirm degree predicted population attributable risk drug induced haemolysis lower would predicted cross sectional surveys",
        "mesh_terms": [
            "Antimalarials",
            "Cross-Sectional Studies",
            "Glucosephosphate Dehydrogenase",
            "Glucosephosphate Dehydrogenase Deficiency",
            "Hemolysis",
            "Humans",
            "Malaria",
            "Malaria, Falciparum",
            "Malaria, Vivax",
            "Primaquine"
        ],
        "source": "https://pubmed.ncbi.nlm.nih.gov/35544453/",
        "source_type": "Bangladesh-specific"
    },
    {
        "pmid": "35532103",
        "title": "\"<i>In silico</i> identification of ethoxy phthalimide pyrazole derivatives as IL-17A and IL-18 targeted gouty arthritis agents\".",
        "abstract": "Two proinflammatory cytokines IL17A IL18 observed elevated serum gout patient play crucial role development worsening inflammation severe effects present study combined molecular docking molecular dynamic study MMPBSA analysis study effectiveness ethoxy phthalimide pyrazole derivative series 3a 3e potential inhibitor cytokine IL17A IL18 druggable targets binding energy docked series range 135 100 kcalmol extensively interacts amino acid active pocket IL17A IL18 Compound 3e lowest binding energy IL17A 126 kcalmol compared control allopurinol 332 kcalmol IL18 compound 3a seems lowest binding energy 96 kcalmol compared control allopurinol 318 kcalmol MD simulation studies compound 3a form stable energetically stabilized complex target protein Depending property bound IL17A3a IL183a complex compared mean MMPBSA analysis derivative used scaffold develop promising IL17A IL18 inhibitor assess potential gouty arthritis related diseases Communicated Ramaswamy H Sarma",
        "mesh_terms": [
            "Humans",
            "Interleukin-18",
            "Arthritis, Gouty",
            "Interleukin-17",
            "Allopurinol",
            "Molecular Docking Simulation",
            "Antineoplastic Agents",
            "Cytokines",
            "Phthalimides",
            "Pyrazoles",
            "Molecular Dynamics Simulation"
        ],
        "source": "https://pubmed.ncbi.nlm.nih.gov/35532103/",
        "source_type": "Bangladesh-specific"
    },
    {
        "pmid": "35419560",
        "title": "Identification of 1, 2, 4-Triazine and Its Derivatives Against Lanosterol 14-Demethylase (CYP51) Property of <i>Candida albicans:</i> Influence on the Development of New Antifungal Therapeutic Strategies.",
        "abstract": "research aim find whether 1 2 4triazine derivative antifungal effect protect human infection iCandida albicansi Molecular docking molecular dynamic simulation widely used modern drug design target particular protein ligand interested using molecular docking molecular dynamic modeling investigate interaction derivative 1 2 4triazine enzyme Lanosterol 14demethylase CYP51 iCandida albicansi inhibition iCandida albicansi CYP51 main goal research 1 2 4triazine derivative docked CYP51 enzyme involved iCandida albicansi Multidrug Drug Resistance MDR Autodock tool used identify binding affinity molecule target proteins Compared conventional fluconazole molecular docking result indicated drug high binding affinity CYP51 protein form unbound interaction hydrogen bond active residue surrounding allosteric residues docking contact made using 10 n MD simulation nine molecules RMSD RMSF hydrogen bonds Rg confirm conclusions addition compound expected favorable pharmacological profile low toxicity compound offered scaffold development new antifungal drug candidate future iin vitroi testing",
        "mesh_terms": [],
        "source": "https://pubmed.ncbi.nlm.nih.gov/35419560/",
        "source_type": "Bangladesh-specific"
    },
    {
        "pmid": "35402627",
        "title": "Prospective Asian plants with corroborated antiviral potentials: Position standing in recent years.",
        "abstract": "Viral disease extremely widespread infection caused viruses Amongst numerous illnesses viral infection challenged human existence severely history mankind new virus emerged presented u new tests range viral infection varies familiar infectious disease common cold flu wart severe ailment AIDS Ebola COVID19 world racing find effective cure newly evolving viruses Toxic effects nonselectivity drug resistance high price common complication conventional treatment procedures Nature marvelous source phytoconstituents incredible variety biological activities tradition medicinal plant utilized treatment countless infectious disease worldwide contain broad spectrum activities Modern drug discovery development technique offer highly efficient separation techniques inauguration vectorbased scheme original infectious virus cloned noninfectious one antiviral screening targets objective review gather available data 20 cultivated native plant Asia giving antiviral activity provide comprehensive information phytochemical analysis plant potential antiviral compound isolated plants",
        "mesh_terms": [],
        "source": "https://pubmed.ncbi.nlm.nih.gov/35402627/",
        "source_type": "Bangladesh-specific"
    },
    {
        "pmid": "35277538",
        "title": "Computational identification of host genomic biomarkers highlighting their functions, pathways and regulators that influence SARS-CoV-2 infections and drug repurposing.",
        "abstract": "pandemic threat COVID19 severely destroyed human life well economy around world Although vaccination reduced outspread people still suffering due unstable RNA sequence pattern SARSCoV2 demand supplementary drugs explore novel drug target proteins study transcriptomics RNASeq data generated SARSCoV2 infection control sample analyzed identified 109 differentially expressed gene DEGs utilized identify 10 hubgenesproteins TLR2 USP53 GUCY1A2 SNRPD2 NEDD9 IGF2 CXCL2 KLF6 PAG1 ZFP36 proteinprotein interaction PPI network analysis GO functional KEGG pathway enrichment analysis hubDEGs revealed important function signaling pathway significantly associated SARSCoV2 infections interaction network analysis identified 5 TFs protein 6 miRNAs key regulator hubDEGs Considering 10 hubproteins 5 key TFsproteins drug target receptors performed docking analysis SARSCoV2 3CL proteaseguided top listed 90 FDA approved drugs found Torin2 Rapamycin Radotinib Ivermectin Thiostrepton Tacrolimus Daclatasvir top ranked seven candidate drugs investigated resistance performance already published COVID19 causing topranked 11 independent 8 protonated receptor protein molecular docking analysis found strong binding affinities indicates proposed drug effective stateofthearts alternative independent receptor protein also Finally investigated stability top three drug Torin2 Rapamycin Radotinib using 100 n MDbased MMPBSA simulation two topranked proposed receptor TLR2 USP53 independent receptor IRF7 STAT1 observed stable performance Therefore proposed drug might play vital role treatment different variant SARSCoV2 infections",
        "mesh_terms": [
            "COVID-19",
            "Case-Control Studies",
            "Drug Repositioning",
            "Gene Regulatory Networks",
            "Genetic Markers",
            "Humans",
            "Molecular Docking Simulation",
            "Protein Interaction Maps",
            "SARS-CoV-2",
            "COVID-19 Drug Treatment"
        ],
        "source": "https://pubmed.ncbi.nlm.nih.gov/35277538/",
        "source_type": "Bangladesh-specific"
    },
    {
        "pmid": "34997152",
        "title": "A comprehensive analysis of selected medicines collected from private drug outlets of Dhaka city, Bangladesh in a simple random survey.",
        "abstract": "Comprehensive data needed prevent substandard falsified SF medicine pose major risk human health assess quality selected medicines sample collected random private drug outlet Dhaka North South City Corporation Bangladesh Sample analysis included visual observation packaging authenticity samples legitimacy registration verification manufacturer physicochemical analysis price Chemical analysis sample performed using portable Raman spectroscopy highperformance liquid chromatography according pharmacopoeia Several discrepancy noted visual observation samples Among 189 collected sample esomeprazole ESM cefixime CFIX amoxicillinclavulanic acid CVAAMPC 212 confirmed authentic 913 manufacturer confirmed legitimate 21 sample unregistered Chemical analysis sample revealed 95 95 CI 57146 sample SFs Falsified sample quality variation generic branded sample detected Raman spectroscopic analysis Overall sample price satisfactory relative international reference price study document availability poorquality medicines demonstrating need immediate attention national medicine regulatory authority",
        "mesh_terms": [
            "Bangladesh",
            "Commerce",
            "Drug Contamination",
            "Drug Packaging",
            "Drugs, Generic",
            "Quality Control"
        ],
        "source": "https://pubmed.ncbi.nlm.nih.gov/34997152/",
        "source_type": "Bangladesh-specific"
    },
    {
        "pmid": "34967848",
        "title": "Cancer Incidence, Mortality, Years of Life Lost, Years Lived With Disability, and Disability-Adjusted Life Years for 29 Cancer Groups From 2010 to 2019: A Systematic Analysis for the Global Burden of Disease Study 2019.",
        "abstract": "Global Burden Diseases Injuries Risk Factors Study 2019 GBD 2019 provided systematic estimate incidence morbidity mortality inform local international effort toward reducing cancer burden estimate cancer burden trend globally 204 country territory Sociodemographic Index SDI quintiles 2010 2019 GBD 2019 estimation method used describe cancer incidence mortality year lived disability year life lost disabilityadjusted life year DALYs 2019 past decade Estimates also provided quintiles SDI composite measure educational attainment income per capita total fertility rate younger 25 years Estimates include 95 uncertainty interval UIs 2019 estimated 236 million 95 UI 222249 million new cancer case 172 million excluding nonmelanoma skin cancer 100 million 95 UI 936106 million cancer death globally estimated 250 million 235264 million DALYs due cancer Since 2010 represented 263 95 UI 203323 increase new cases 209 95 UI 142276 increase deaths 160 95 UI 93228 increase DALYs Among 22 group disease injury GBD 2019 study cancer second cardiovascular disease number deaths year life lost DALYs globally 2019 Cancer burden differed across SDI quintiles proportion year lived disability contributed DALYs increased SDI ranging 14 1118 low SDI quintile 57 4271 high SDI quintile high SDI quintile highest number new case 2019 middle SDI quintile highest number cancer death DALYs 2010 2019 largest percentage increase number case death occurred low lowmiddle SDI quintiles result systematic analysis suggest global burden cancer substantial growing burden differing SDI result provide comprehensive comparable estimate potentially inform effort toward equitable cancer control around world",
        "mesh_terms": [
            "Disability-Adjusted Life Years",
            "Global Burden of Disease",
            "Global Health",
            "Humans",
            "Incidence",
            "Neoplasms",
            "Prevalence",
            "Quality-Adjusted Life Years",
            "Risk Factors"
        ],
        "source": "https://pubmed.ncbi.nlm.nih.gov/34967848/",
        "source_type": "Bangladesh-specific"
    },
    {
        "pmid": "34962984",
        "title": "The cost implications of a polypill for primary prevention in the TIPS-3 trial.",
        "abstract": "International Polycap Study 3 TIPS3 trial demonstrated polypill containing cholesterol multiple bloodpressurelowering drug reduces cardiovascular event 20 compared placebo people without cardiovascular disease polypill plus aspirin led 31 relative risk reduction cardiovascular disease event compared double placebo report regional variation cost affordability polypill based TIPS3 trial Countries categorized using World Bank economic groups lowermiddleincome uppermiddleincome highincome countries Countryspecific cost obtained hospitalization events procedures nonstudy medication 2019 US dollars Polypill price based cheapest equivalent substitute CES component polypill vs placebo difference cost 46 year trial 291 95 confidence interval CI 243339 per participant lowermiddleincome countries 1068 95 CI 9921144 uppermiddleincome countries 48 95 CI 271 367 highincome countries Results similar polypill plus aspirin vs double placebo cases polypill affordable group using monthly household capacity pay threshold 4 gross national income per capita use polypill CES TIPS3 increase cost lowermiddleincome country uppermiddleincome country affordable country various economic level cost neutral dominant highincome countries",
        "mesh_terms": [
            "Humans",
            "Aspirin",
            "Cardiovascular Diseases",
            "Drug Combinations",
            "Hydroxymethylglutaryl-CoA Reductase Inhibitors",
            "Platelet Aggregation Inhibitors",
            "Primary Prevention"
        ],
        "source": "https://pubmed.ncbi.nlm.nih.gov/34962984/",
        "source_type": "Bangladesh-specific"
    },
    {
        "pmid": "34928380",
        "title": "Genome-wide chromosomal association of Upf1 is linked to Pol II transcription in Schizosaccharomyces pombe.",
        "abstract": "Although RNA helicase Upf1 hitherto examined mostly relation cytoplasmic role nonsense mediated mRNA decay NMD report highthroughput ChIP data indicating genomewide association Upf1 active gene Schizosaccharomyces pombe association RNase sensitive correlate Pol II transcription mRNA expression levels Changes Pol II occupancy detected Upf1 deficient upf1Δ strain prevalently gene showing high Upf1 relative Pol II association wildtype Additionally increased Ser2 Pol II signal detected highly transcribed gene examined ChIPqPCR Furthermore upf1Δ cell hypersensitive transcription elongation inhibitor 6azauracil significant proportion gene associated Upf1 wildtype condition also misregulated upf1Δ data envisage operating nascent transcript Upf1 might influence Pol II phosphorylation transcription",
        "mesh_terms": [
            "Gene Expression Regulation, Fungal",
            "Genome, Fungal",
            "Phosphorylation",
            "RNA Helicases",
            "RNA Polymerase II",
            "Schizosaccharomyces",
            "Schizosaccharomyces pombe Proteins",
            "Transcriptional Activation"
        ],
        "source": "https://pubmed.ncbi.nlm.nih.gov/34928380/",
        "source_type": "Bangladesh-specific"
    },
    {
        "pmid": "34790685",
        "title": "Evaluation of the Partial Replacement of Dietary Fish Meal With Fermented or Untreated Soybean Meal in Juvenile Silver Barb, <i>Barbonymus gonionotus</i>.",
        "abstract": "Fish meal FM excellent protein lipid profile However FM losing acceptability substituted plant protein due FM high price high demand sustainability issue global aquaculture production study experimental diet prepared substituting FM fermented soybean meal FSM normal untreated soybean meal SM assess effect growth hematology innate immunity gut physiology digestive enzyme activity juvenile silver barb iBarbonymus gonionotusi Five diets is 40 FM FM 40 20 FM  20 FSM FM 20  FSM 20 20 FM  20 SM FM 20  SM 20 40 FSM FSM 40 40 SM SM 40 fed fish two time daily 90 days 90 day feeding trial FM 40 FM 20  FSM 20 FM 20  SM 20 diet group showed significantly higher weight gain WG specific growth rate SGR compared FSM 40 SM 40 diets Hepatosomatic index HSI viscerosomatic index VSI significantly higher fish fed FSM 40 SM 40 diet fish fed FM 40 diet Hematocrit hemoglobin erythrocyte count significantly lower fish fed SM 40 diet compared fish fed FM 40 FM 20  FSM 20 diets Superoxide dismutase catalase activity liver significantly higher fish fed SM 40 diet compared fish fed FM 40 diet However serum thiobarbituric acid reactive substance fish fed experimental diet unaltered Fish showed significant reduction villus height Vh anterior posterior intestine fish fed FSM 40 SM 40 diets whereas muscular thickness opposite finding Vh Digestive enzyme activity intestine significantly higher fish fed FM 40 diet compared SM 40 diet result present study revealed 50 FM replaced FSM SM source protein without affecting growth juvenile silver barb",
        "mesh_terms": [],
        "source": "https://pubmed.ncbi.nlm.nih.gov/34790685/",
        "source_type": "Bangladesh-specific"
    },
    {
        "pmid": "34758422",
        "title": "Results of the COVID-19 mental health international for the general population (COMET-G) study.",
        "abstract": "published empirical data effect COVID19 mental health now large international study COVID19 pandemic online questionnaire gathered data 55589 participant 40 country 6485 female aged 3580 ± 1361 3405 male aged 3490±1329 110 aged 3164±1315 Distress probable depression identified use previously developed cutoff algorithm respectively Descriptive statistic calculated Chisquare tests multiple forward stepwise linear regression analysis Factorial Analysis Variance ANOVA tested relation among variables Probable depression detected 1780 distress 1671 significant percentage reported deterioration mental state family dynamic everyday lifestyle Persons history mental disorder higher rate current depression 3182 vs 1307 least half participant accepting at least moderate degree nonbizarre conspiracy highest Relative Risk RR develop depression associated history Bipolar disorder selfharmattempts RR  588 Suicidality increased person without history mental disorder Based result model developed final model revealed multiple vulnerability interplay leading simple anxiety probable depression suicidality distress could practical utility since many factor modifiable Future research intervention specifically focus them",
        "mesh_terms": [
            "Adult",
            "Anxiety",
            "COVID-19",
            "Depression",
            "Female",
            "Global Burden of Disease",
            "Humans",
            "Male",
            "Mental Health",
            "Middle Aged",
            "Pandemics",
            "SARS-CoV-2",
            "Stress, Psychological",
            "Suicidal Ideation"
        ],
        "source": "https://pubmed.ncbi.nlm.nih.gov/34758422/",
        "source_type": "Bangladesh-specific"
    },
    {
        "pmid": "34503501",
        "title": "Pharmacies in informal settlements: a retrospective, cross-sectional household and health facility survey in four countries.",
        "abstract": "Slums informal settlement characterize large city LMIC Previous evidence suggests pharmacy may frequently used source primary care LMICs pharmacy service variable quality However evidence pharmacy use availability limited slum populations conducted household individual healthcare provider survey qualitative observation pharmacy pharmacy use seven slum site four country Nigeria Kenya Pakistan Bangladesh pharmacy 1200 household site sampled Adults child surveyed use healthcare service pharmacy observed services equipment stock documented completed 7692 household 7451 individual adults 2633 individual child surveys 157 survey pharmacy located within seven sites Visit rate pharmacy drug seller varied 01 Nigeria 30 Bangladesh visit per personyear almost new conditions found highly variable condition constituted pharmacy across site pharmacy employ qualified pharmacist Analgesics antibiotic widely available category medications particularly chronic illness often available anywhere majority pharmacy lacked basic equipment thermometer weighing scales Pharmacies locally widely available resident slums However condition facility availability medicine poor price relatively high Pharmacies may represent large untapped resource improving access primary care urban poor",
        "mesh_terms": [
            "Adult",
            "Child",
            "Cross-Sectional Studies",
            "Health Facilities",
            "Humans",
            "Pharmaceutical Services",
            "Pharmacies",
            "Retrospective Studies"
        ],
        "source": "https://pubmed.ncbi.nlm.nih.gov/34503501/",
        "source_type": "Bangladesh-specific"
    },
    {
        "pmid": "34450083",
        "title": "Worldwide trends in hypertension prevalence and progress in treatment and control from 1990 to 2019: a pooled analysis of 1201 population-representative studies with 104 million participants.",
        "abstract": "Hypertension detected primary healthcare level lowcost treatment effectively control hypertension aimed measure prevalence hypertension progress detection treatment control 1990 2019 200 country territories used data 1990 2019 people aged 3079 year populationrepresentative study measurement blood pressure data blood pressure treatment defined hypertension systolic blood pressure 140 mm Hg greater diastolic blood pressure 90 mm Hg greater taking medication hypertension applied Bayesian hierarchical model estimate prevalence hypertension proportion people hypertension previous diagnosis detection taking medication hypertension treatment whose hypertension controlled 14090 mm Hg control model allowed trend time nonlinear vary age number people aged 3079 year hypertension doubled 1990 2019 331 95 credible interval 306359 million woman 317 292344 million men 1990 626 584668 million woman 652 604698 million men 2019 despite stable global agestandardised prevalence 2019 agestandardised hypertension prevalence lowest Canada Peru men women Taiwan South Korea Japan country western Europe including Switzerland Spain UK women several lowincome middleincome country Eritrea Bangladesh Ethiopia Solomon Islands men Hypertension prevalence surpassed 50 woman two country men nine countries central eastern Europe central Asia Oceania Latin America Globally 59 5562 woman 49 4652 men hypertension reported previous diagnosis hypertension 2019 47 4351 woman 38 3541 men treated Control rate among people hypertension 2019 23 2027 woman 18 1621 men 2019 treatment control rate highest South Korea Canada Iceland treatment 70 control 50 followed USA Costa Rica Germany Portugal Taiwan Treatment rate less 25 woman less 20 men Nepal Indonesia country subSaharan Africa Oceania Control rate 10 woman men country men country north Africa central south Asia eastern Europe Treatment control rate improved country since 1990 found little change country subSaharan Africa Oceania Improvements largest highincome countries central Europe uppermiddleincome recently highincome country including Costa Rica Taiwan Kazakhstan South Africa Brazil Chile Turkey Iran Improvements detection treatment control hypertension varied substantially across countries middleincome country outperforming highincome nations dual approach reducing hypertension prevalence primary prevention enhancing treatment control achievable highincome country also lowincome middleincome settings WHO",
        "mesh_terms": [
            "Adult",
            "Aged",
            "Antihypertensive Agents",
            "Female",
            "Global Health",
            "Humans",
            "Hypertension",
            "Male",
            "Middle Aged",
            "Prevalence"
        ],
        "source": "https://pubmed.ncbi.nlm.nih.gov/34450083/",
        "source_type": "Bangladesh-specific"
    },
    {
        "pmid": "33824913",
        "title": "An open dataset of <i>Plasmodium falciparum</i> genome variation in 7,000 worldwide samples.",
        "abstract": "MalariaGEN datasharing network enables group around world work together genomic epidemiology malaria describe new release curated genome variation data 7000 iPlasmodium falciparumi sample MalariaGEN partner study 28 malariaendemic countries Highquality genotype call 3 million single nucleotide polymorphism SNPs short indels produced using standardised analysis pipeline Copy number variant associated drug resistance structural variant cause failure rapid diagnostic test also analysed Almost sample showed genetic evidence resistance least one antimalarial drug sample Southeast Asia carried marker resistance six commonlyused drugs Genes expressed mosquito stage parasite lifecycle prominent among locus show strong geographic differentiation continuing enlarge open data resource aim facilitate research evolutionary process affecting malaria control accelerate development surveillance toolkit required malaria elimination",
        "mesh_terms": [],
        "source": "https://pubmed.ncbi.nlm.nih.gov/33824913/",
        "source_type": "Bangladesh-specific"
    },
    {
        "pmid": "34249838",
        "title": "The Current Situation Regarding Long-Acting Insulin Analogues Including Biosimilars Among African, Asian, European, and South American Countries; Findings and Implications for the Future.",
        "abstract": "bBackgroundb Diabetes mellitus rate continue rise coupled increasing cost associated complication appreciably increased global expenditure recent years risk complication enhanced poor glycaemic control including hypoglycaemia Longacting insulin analogue developed reduce hypoglycaemia improve adherence considerably higher cost though impacted funding use Biosimilars help reduce medicine costs However introduction affected number factors include originator company dropping price well promoting patented higher strength 300 IUml insulin glargine also concern different device manufacturers bObjectiveb assess current utilisation rate insulins especially longacting insulin analogues rationale pattern seen across multiple country inform strategy enhance future utilisation longacting insulin analogue biosimilars benefit key stakeholders bOur approachb Multiple approach including assessing utilisation expenditure price insulins including biosimilar insulin glargine across multiple continent countries bResultsb considerable variation use longacting insulin analogue percentage insulin prescribed dispensed across country continents ranged limited use longacting insulin analogue among African country compared routine funding use across Europe view perceived benefits Increasing use also seen among Asian country including Bangladesh India similar reasons However concern cost value limited use across Africa Brazil Pakistan though limited use biosimilar insulin glargine 100 IUml compared recent biosimilars especially among European country Korea principally driven small price difference reality originator biosimilars coupled increasing use patented 300 IUml formulation number activity identified enhance future biosimilar use included reimbursing biosimilar longacting insulin analogues introducing prescribing target increasing competition among manufacturer including stimulating local production bConclusionsb concern availability use insulin glargine biosimilars despite lower costs addressed multiple activities",
        "mesh_terms": [
            "Africa",
            "Bangladesh",
            "Biosimilar Pharmaceuticals",
            "Brazil",
            "Europe",
            "Hypoglycemic Agents",
            "India",
            "Insulin, Long-Acting",
            "Pakistan",
            "Republic of Korea"
        ],
        "source": "https://pubmed.ncbi.nlm.nih.gov/34249838/",
        "source_type": "Bangladesh-specific"
    },
    {
        "pmid": "34182555",
        "title": "The Burden of Dementia due to Down Syndrome, Parkinson's Disease, Stroke, and Traumatic Brain Injury: A Systematic Analysis for the Global Burden of Disease Study 2019.",
        "abstract": "light increasing trend global number individual affected dementia lack available diseasemodifying therapies necessary fully understand quantify global burden dementia work aimed estimate proportion dementia due syndrome Parkinsons disease clinical stroke traumatic brain injury TBI globally world region order better understand contribution clinical disease dementia prevalence literature review obtained data relative risk dementia condition estimated relative risk age using Bayesian metaregression tool calculated population attributable fraction PAFs proportion dementia attributable condition using estimate relative risk prevalence estimate condition Global Burden Disease Study 2019 Finally multiplied estimate dementia prevalence calculate number dementia case attributable condition clinical condition relative risk dementia decreased age Relative risk highest syndrome followed Parkinsons disease stroke TBI However due high prevalence stroke PAF dementia due stroke highest Together syndrome Parkinsons disease stroke TBI explained 100 95 UI 60165 global prevalence dementia Ten percent dementia prevalence globally could explained syndrome Parkinsons disease stroke TBI quantification proportion dementia attributable 4 condition constitutes small contribution overall understanding cause dementia However epidemiological research modifiable risk factor well basic science research focused elucidating intervention approach prevent delay neuropathological change commonly characterize dementia critically important future effort prevent treat disease",
        "mesh_terms": [
            "Bayes Theorem",
            "Brain Injuries, Traumatic",
            "Dementia",
            "Down Syndrome",
            "Global Burden of Disease",
            "Global Health",
            "Humans",
            "Parkinson Disease",
            "Prevalence",
            "Quality-Adjusted Life Years",
            "Risk Factors",
            "Stroke"
        ],
        "source": "https://pubmed.ncbi.nlm.nih.gov/34182555/",
        "source_type": "Bangladesh-specific"
    },
    {
        "pmid": "34166174",
        "title": "Current utilization patterns for long-acting insulin analogues including biosimilars among selected Asian countries and the implications for the future.",
        "abstract": "Prevalence rate diabetes mellitus continue rise which coupled increasing cost complications appreciably increased expenditure recent years Poor glycaemic control including hypoglycaemia enhances complication rate associated morbidity mortality costs Consequently need addressed Whilst majority patient diabetes type2 diabetes considerable number patient diabetes require insulin help control diabetes Longacting insulin analogue developed reduce hypoglycaemia associated insulin help improve adherence concern However considerably higher cost impacted funding use especially country affordability issues Biosimilars help reduce cost longacting insulin analogue thereby increasing available choices However availability use longacting insulin analogue affected limited price reduction versus originator limited demandside initiative encourage use Consequently wanted assess current utilisation rate longacting insulin analogues especially biosimilars rationale pattern seen across multiple Asian country ranging Japan highincome Pakistan lowerincome inform future strategies Multiple approach including assessing utilization price insulin including biosimilars among six Asian country comparing finding especially middleincome countries Typically increasing use longacting insulin analogue among selected Asian countries especially case enhanced biosimilars Bangladesh India Malaysia reflecting perceived benefits However limited use Pakistan due issue affordability similar number African countries high use biosimilars Bangladesh India Malaysia helped issue affordability local production limited use biosimilars Japan Korea reflects limited price reduction demandside initiative similar number European countries Increasing use longacting insulin analogue across country welcomed adding range insulin available increasingly includes biosimilars number activity needed enhance use longacting insulin analogue biosimilars Japan Korea Pakistan",
        "mesh_terms": [
            "Asia",
            "Biosimilar Pharmaceuticals",
            "Diabetes Mellitus, Type 2",
            "Humans",
            "Hypoglycemic Agents",
            "Insulin",
            "Insulin, Long-Acting",
            "Japan",
            "Pakistan"
        ],
        "source": "https://pubmed.ncbi.nlm.nih.gov/34166174/",
        "source_type": "Bangladesh-specific"
    },
    {
        "pmid": "34051920",
        "title": "Spatial, temporal, and demographic patterns in prevalence of chewing tobacco use in 204 countries and territories, 1990-2019: a systematic analysis from the Global Burden of Disease Study 2019.",
        "abstract": "Chewing tobacco type smokeless tobacco use less attention global health community smoked tobacco use However practice popular many part world linked several adverse health outcomes Understanding trend prevalence age time location sex important policy setting relation monitoring assessing commitment Framework Convention Tobacco Control estimated prevalence chewing tobacco use part Global Burden Diseases Injuries Risk Factors Study 2019 using modelling strategy used information multiple type smokeless tobacco products generated time series prevalence chewing tobacco use among individual aged 15 year older 1990 2019 204 country territories including agesex specific estimates also compared trend smoked tobacco time period 2019 273·9 million 95 uncertainty interval 258·5 290·9 people aged 15 year older used chewing tobacco global agestandardised prevalence chewing tobacco use 4·72 4·46 5·01 228·2 million 213·6 244·7 83·29 82·15 84·42 chewing tobacco user lived south Asia region Prevalence among young people aged 1519 year 10 seven location 2019 Although global agestandardised prevalence smoking tobacco use decreased significantly 1990 2019 annualised rate change 1·21 1·26 1·16 similar progress observed chewing tobacco 0·46 0·13 0·79 Among 12 highest prevalence country Bangladesh Bhutan Cambodia India Madagascar Marshall Islands Myanmar Nepal Pakistan Palau Sri Lanka Yemen Yemen significant decrease prevalence chewing tobacco use among male 1990 2019 0·94 1·72 0·14 compared nine 12 country significant decrease prevalence smoking tobacco Among females none 12 country significant decrease prevalence chewing tobacco use whereas seven 12 country significant decrease prevalence tobacco smoking use period Chewing tobacco remains substantial public health problem several region world predominantly south Asia found little change prevalence chewing tobacco use 1990 2019 control effort much larger effect prevalence smoking tobacco use chewing tobacco use countries Mitigating health effect chewing tobacco requires stronger regulation policy specifically target use chewing tobacco especially country high prevalence Bloomberg Philanthropies Bill  Melinda Gates Foundation",
        "mesh_terms": [
            "Adolescent",
            "Adult",
            "Age Distribution",
            "Female",
            "Global Burden of Disease",
            "Global Health",
            "Health Status",
            "Humans",
            "Male",
            "Middle Aged",
            "Population Surveillance",
            "Prevalence",
            "Quality-Adjusted Life Years",
            "Risk Factors",
            "Sex Distribution",
            "Smoking Cessation",
            "Smoking Prevention",
            "Socioeconomic Factors",
            "Tobacco, Smokeless",
            "Young Adult"
        ],
        "source": "https://pubmed.ncbi.nlm.nih.gov/34051920/",
        "source_type": "Bangladesh-specific"
    },
    {
        "pmid": "34030931",
        "title": "\"I held on to the police's leg for mercy\": Experiences of adversity, risk and harm among people who inject drugs during an anti-drug drive in Dhaka, Bangladesh.",
        "abstract": "number country across Asia instituted drug wars aimed eradicating drug supply consumption war often employ strategy like arbitrary arrest detention increased surveillance harassment sometimes extrajudicial killings However measure shown effectively eliminate drug supply consumption rather often predispose people use drug increased risk harm drug war declared form antidrug drive ADD Bangladesh 2018 article examined impact ADD drug injecting activity harm reduction service uptake among people inject drug PWID ethnographic study conducted Dhaka Bangladesh Study participant included PWID harm reduction service provider drug alcohol experts Data collection consisted 2500 hour observations 25 indepth interviews five focus group discussion 15 key informant interviews Data analysed using thematic analysis ADD operation activity subjected PWID multifaceted form violence harassment including extrajudicial killings significantly affected drug procurement drug using practice led increased needle syringe sharing likely increase HIV transmission gradual disappearance established drug markets alongside emergence new one alternate locations resulted dislocation PWID outreach service increased risky injecting practice needle syringe sharing new unfamiliar injecting partners harm compounded unpredictable drug supply price increase stemming ADD turn also increased needle syringe sharing Harm reduction outreach service able adequately adapt volatile dynamic risky nature ADD ADD precipitated risky injecting practice also hindered effective implementation harm reduction outreach service thus undermined public health warrant concerted effort nurture local evidencebased harm reduction approach opposed punitive measures",
        "mesh_terms": [
            "Asia",
            "Bangladesh",
            "HIV Infections",
            "Harm Reduction",
            "Humans",
            "Leg",
            "Needle Sharing",
            "Pharmaceutical Preparations",
            "Police",
            "Substance Abuse, Intravenous"
        ],
        "source": "https://pubmed.ncbi.nlm.nih.gov/34030931/",
        "source_type": "Bangladesh-specific"
    },
    {
        "pmid": "33980257",
        "title": "Implementing radical cure diagnostics for malaria: user perspectives on G6PD testing in Bangladesh.",
        "abstract": "radical cure Plasmodium vivax requires treatment 8aminoquinoline drug primaquine tafenoquine eradicate liver hypnozoite stages reactivate cause relapsing infections Safe treatment regimen require prior screening patient glucose6phosphate dehydrogenase G6PD deficiency avoid potential lifethreatening drug induced haemolysis Testing rarely available malaria endemic countries needed support routine use radical cure study investigates enduser perspective Bangladesh introduction quantitative G6PD test SD Biosensor STANDARD™ G6PD analyser support malaria elimination perspective user SD Biosensor test analysed using semistructured interview focus group discussion health care provider malaria programme officer Bangladesh Key emerging theme regarding feasibility introducing test routine practice including perceived barriers analysed total 63 participant interviewed Participants emphasized lifesaving potential biosensor raised concern including impact limited staff time high workload technical aspect device Participants highlighted many P vivax patient implement G6PD testing owing challenge funding workload complex testing infrastructure Implementing biosensor would require flexibility improvisation deal remote sites overcoming low index suspicion mutual interplay declining patient number reluctance test approach would generate new form evidence justify introduction policy carefully consider question deployment given declining patient numbers result study show that elimination context importance malaria need maintained policy maker affected communities case ensuring P vivax PQ treatment G6PD deficiency remain visible Availability new technologies biosensor fuel ongoing debate priority allocating resource must adapted constantly evolving target Technical logistical concern regarding biosensor addressed future product designs adequate training strengthened supply chains careful planning communication advocacy staff interaction health system levels",
        "mesh_terms": [
            "Bangladesh",
            "Diagnostic Tests, Routine",
            "Glucosephosphate Dehydrogenase Deficiency",
            "Health Personnel",
            "Humans",
            "Malaria, Vivax"
        ],
        "source": "https://pubmed.ncbi.nlm.nih.gov/33980257/",
        "source_type": "Bangladesh-specific"
    },
    {
        "pmid": "33734004",
        "title": "Ongoing efforts to improve the management of patients with diabetes in Bangladesh and the implications.",
        "abstract": "Prevalence rate patient diabetes growing across countries Bangladesh exception Associated cost also increasing driven cost associated complication diabetes including hypoglycemia Longacting insulin analogue developed reduce hypoglycemia well improve patient comfort adherence However appreciably expensive reducing affordability use Biosimilars offer way forward Consequently need document current prescribing dispensing rate longacting insulin analogue across Bangladesh including current price differences result affordability issues Mixed method approach including surveying prescribing practice hospital coupled dispensing practice price among community pharmacy drug store across Bangladesh method adopted since public hospital dispense insulin soluble insulin freeofcharge fund run longacting insulin analogue purchased community stores growing prescribing dispensing longacting insulin Bangladesh recent years accounting 80 insulin dispensed minority stores increase helped growing prescribing dispensing biosimilar insulin glargine lower cost originator trend likely continue envisaged growth number patients Consequently Bangladesh serve exemplar low middleincome country struggling fund longacting insulin analogue patients encouraging see continued growth prescribing dispensing longacting insulin analogue Bangladesh via increasing availability biosimilars likely continue benefitting key stakeholder groups",
        "mesh_terms": [
            "Bangladesh",
            "Biosimilar Pharmaceuticals",
            "Diabetes Mellitus",
            "Drug Utilization",
            "Humans",
            "Hypoglycemic Agents",
            "Insulin, Long-Acting",
            "Practice Patterns, Physicians'"
        ],
        "source": "https://pubmed.ncbi.nlm.nih.gov/33734004/",
        "source_type": "Bangladesh-specific"
    },
    {
        "pmid": "33353250",
        "title": "Essential Medicines in Universal Health Coverage: A Scoping Review of Public Health Law Interventions and How They Are Measured in Five Middle-Income Countries.",
        "abstract": "study exist legal intervention national laws essential medicine part universal health coverage middleincome countries effect law measured study aim critically assess whether law related universal health coverage use five objective public health law promote medicine affordability financing understand access medicine achieved law measured comparative case study five middleincome country Ecuador Ghana Philippines South Africa Ukraine us public health law framework guide content analysis national law scoping review empirical evidence measuring access medicines Sixty law included country write national law a health equity objectives b remedy userspatients sanction stakeholders c economic policy regulatory objective financing except South Africa pricing benefit selection except South Africa d information dissemination objective ex medicine price except Ghana e public health infrastructure 17 study included scoping review evaluate law economic policy regulatory objective ini  14 articles health equity ini  10 information dissemination ini  3 infrastructure ini  2 sanction ini  1 not mutually exclusive Crosssectional descriptive design ini  8 articles time series analysis ini  5 frequent designs Change patients spending medicine frequent outcome measure ini  5 Although legal intervention pharmaceutical middleincome country commonly use objective public health law intended unintended effect economic policy regulation frequently investigated",
        "mesh_terms": [
            "Adult",
            "Cross-Sectional Studies",
            "Developing Countries",
            "Diabetes Mellitus, Type 2",
            "Ecuador",
            "Ghana",
            "Health Care Reform",
            "Health Services Accessibility",
            "Humans",
            "Longitudinal Studies",
            "Philippines",
            "Public Health",
            "Retrospective Studies",
            "South Africa",
            "Ukraine",
            "Universal Health Insurance"
        ],
        "source": "https://pubmed.ncbi.nlm.nih.gov/33353250/",
        "source_type": "Bangladesh-specific"
    },
    {
        "pmid": "33211712",
        "title": "The risk of Plasmodium vivax parasitaemia after P. falciparum malaria: An individual patient data meta-analysis from the WorldWide Antimalarial Resistance Network.",
        "abstract": "high risk Plasmodium vivax parasitaemia following treatment falciparum malaria study aimed quantify risk associated determinant using individual patient data metaanalysis order identify population policy universal radical cure combining artemisininbased combination therapy ACT hypnozoitocidal antimalarial drug would beneficial systematic review Medline Embase Web Science Cochrane Database Systematic Reviews identified efficacy study uncomplicated falciparum malaria treated ACT undertaken region coendemic P vivax 1 January 1960 5 January 2018 Data eligible study pooled using standardised methodology risk P vivax parasitaemia day 42 63 associated risk factor investigated multivariable Cox regression analyses Study quality assessed using tool developed Joanna Briggs Institute study registered International Prospective Register Systematic Reviews PROSPERO CRD42018097400 total 42 study enrolling 15341 patient included analysis including 30 randomised controlled trial 12 cohort studies Overall 14146 922 patient P falciparum monoinfection 1195 78 mixed infection P falciparum P vivax median age 170 year interquartile range IQR  90290 years range  080 years 1584 103 patient younger 5 years 2711 177 patient treated artemetherlumefantrine AL 13 studies 651 42 artesunateamodiaquine AA 6 studies 7340 478 artesunatemefloquine AM 25 studies 4639 302 dihydroartemisininpiperaquine DP 16 studies 14537 patient 948 enrolled AsiaPacific region 684 45 Americas 120 08 Africa day 42 cumulative risk vivax parasitaemia following treatment P falciparum 311 95 CI 289334 AL 141 95 CI 108183 AA 74 95 CI 6781 AM 45 95 CI 3953 DP day 63 risk risen 399 95 CI 366433 424 95 CI 347512 228 95 CI 212244 128 95 CI 114145 respectively multivariable analyses highest rate P vivax parasitaemia 42 day followup patient residing area short relapse periodicity adjusted hazard ratio AHR  62 95 CI 20195 p  0002 patient treated AL AHR  62 95 CI 4685 p  0001 AA AHR  23 95 CI 1437 p  0001 AHR  14 95 CI 1019 p  0028 compared DP patient clear initial parasitaemia within 2 day AHR  18 95 CI 1423 p  0001 analysis limited heterogeneity study population lack data low transmission settings Study quality high metaanalysis found high risk P vivax parasitaemia treatment P falciparum malaria varied significantly studies P vivax infection likely attributable relapse could prevented radical cure including hypnozoitocidal agent however benefit novel strategy vary considerably geographical areas",
        "mesh_terms": [
            "Adolescent",
            "Adult",
            "Aged",
            "Aged, 80 and over",
            "Antimalarials",
            "Artemether, Lumefantrine Drug Combination",
            "Artemisinins",
            "Child",
            "Child, Preschool",
            "Female",
            "Humans",
            "Infant",
            "Malaria",
            "Malaria, Falciparum",
            "Malaria, Vivax",
            "Male",
            "Middle Aged",
            "Parasitemia",
            "Plasmodium vivax",
            "Young Adult"
        ],
        "source": "https://pubmed.ncbi.nlm.nih.gov/33211712/",
        "source_type": "Bangladesh-specific"
    },
    {
        "pmid": "33148540",
        "title": "Availability and affordability of medicines and cardiovascular outcomes in 21 high-income, middle-income and low-income countries.",
        "abstract": "aimed examine relationship access medicine cardiovascular disease CVD major adverse cardiovascular event MACEs among people high risk CVD highincome country HICs upper lower middleincome country UMICs LMICs lowincome country LICs participating Prospective Urban Rural Epidemiology PURE study defined high CVD risk presence following hypertension coronary artery disease stroke smoker diabetes age 55 years Availability affordability blood pressure lowering drugs antiplatelets statin obtained pharmacies Participants categorised group 1all three drug type available affordable group 2all three drug available affordable group 3all three drug available used multivariable Cox proportional hazard model nested clustering country community levels adjusting comorbidities sociodemographic economic factors 163 466 participants 93 200 high CVD risk 21 country mean age 547 49 female these 449 group 1 294 group 2 257 group 3 Compared participant group 1 risk MACEs higher among participant group 2 HR 119 95 CI 107 131 among participant group 3 HR 125 95 CI 108 150 Lower availability affordability essential CVD medicine associated higher risk MACEs mortality Improving access CVD medicine key part strategy lower CVD globally",
        "mesh_terms": [
            "Costs and Cost Analysis",
            "Developing Countries",
            "Female",
            "Humans",
            "Income",
            "Male",
            "Middle Aged",
            "Poverty",
            "Prospective Studies"
        ],
        "source": "https://pubmed.ncbi.nlm.nih.gov/33148540/",
        "source_type": "Bangladesh-specific"
    },
    {
        "pmid": "33107165",
        "title": "Antibiotic exposure among young infants suffering from diarrhoea in Bangladesh.",
        "abstract": "Appropriate rehydration always significant treating diarrhoeal disease children Irrational antibiotic use among diarrhoeal child remained major public health concern Information regarding antibiotic use young infant suffering diarrhoea limited unique aspect research aimed investigate prevalence antibiotic use community among 26 month infant diarrhoeal illness different nutritional status investigated total 5279 infant aged 26 month Dhaka hospital International Centre Diarrhoeal Disease Research Bangladesh September 2018 June 2019 Among them 257 infant suffering severe acute malnutrition SAM History taking antibiotic ascertained direct observation prescription physician bottle antibiotic asking caregiver name antibiotic price close usual market price antibiotic Overall 52 infant received antibiotic hospital admission NonSAM infant higher odds receiving antibiotic adjusted odds ratio aOR  152 95 confidence interval 118 197 P value  0003 compared infant SAM use antibiotic increased age aOR  111 95 confidence interval 106 117 P value0001 Commonly used antibiotic azithromycin 133 ciprofloxacin 77 erythromycin 77 metronidazole 26 proportion receiving ciprofloxacin significantly lower infant SAM compared nonSAM counterpart 27 vs 797 P value  0004 study underscore excessive use antibiotic among diarrhoeal infants already major public health concern low middleincome countries",
        "mesh_terms": [
            "Anti-Bacterial Agents",
            "Bangladesh",
            "Child",
            "Diarrhea",
            "Diarrhea, Infantile",
            "Female",
            "Humans",
            "Infant",
            "Nutritional Status"
        ],
        "source": "https://pubmed.ncbi.nlm.nih.gov/33107165/",
        "source_type": "Bangladesh-specific"
    },
    {
        "pmid": "33082188",
        "title": "Developing core economic parameter sets for asthma studies: a realist review and an analytical framework.",
        "abstract": "develop standardised set economic parameter core economic parameter set economic evaluation asthma studies systematic literature review analytical framework Economic parameter used evaluate cost costeffectiveness healthcare intervention people asthma PubMed Cochrane Database Systematic Reviews National Health Service Economic Evaluation Database Database Abstracts Reviews Effects Health Technology Aaaessment Library starting 1990 Research method based realist review methodology included number nonsequential iterative overlapping components developing analytical framework realist review systematic literature review economic parameters identifying categorising economic parameters producing preliminary list core economic parameters Database search found 2531 publication 224 included systematic review identified 65 economic parameter categorised 11 group enable realist synthesis Parameters related secondary care primary care medication use emergency care work productivity comprised 84 economic parameters analytical framework used investigate rationale behind choice economic parameter studies main framework domain included type intervention research population study design study setting stakeholders perspective Past research thus suggests asthma study parameter depicting use secondary care primary care medication emergency care work productivity considered core economic parameters since apply different type studies Parameters including diagnostics healthcare delivery school activity informal care medical device health utility apply particular type study or research question thus recommended supplemental parameters CRD42017067867",
        "mesh_terms": [
            "Asthma",
            "Cost-Benefit Analysis",
            "Delivery of Health Care",
            "Humans",
            "State Medicine",
            "Systematic Reviews as Topic"
        ],
        "source": "https://pubmed.ncbi.nlm.nih.gov/33082188/",
        "source_type": "Bangladesh-specific"
    },
    {
        "pmid": "32981529",
        "title": "Cost-effectiveness of adrenaline for out-of-hospital cardiac arrest.",
        "abstract": "Prehospital Assessment Role Adrenaline Measuring Effectiveness Drug Administration Cardiac Arrest PARAMEDIC2 trial showed adrenaline improves overall survival neurological outcomes sought determine withintrial lifetime health social care cost benefit associated adrenaline including secondary benefit organ donation estimated costs benefit qualityadjusted life year QALYs incremental costeffectiveness ratio ICERs associated adrenaline 6month trial followup Modelbased analysis explored result altered time horizon extended beyond 6 month scope extended include recipient donated organs withintrial 6 months lifetime horizon economic evaluation focussed trial population produced ICERs £1693003 €1946953 £81070 €93231 per QALY gained 2017 prices respectively reflecting significantly higher mean cost marginally higher mean QALYs adrenaline group probability adrenaline costeffective less 1 across range costeffectiveness thresholds Combined direct economic effect lifetime survivor indirect economic effect organ recipient produced ICER £16086 €18499 per QALY gained adrenaline probability adrenaline costeffective increasing 90 £30000 €34500 per QALY costeffectiveness threshold Adrenaline costeffective directly related cost consequence considered However incorporating indirect economic effect associated transplanted organ substantially alters costeffectiveness suggesting decisionmakers consider complexity direct indirect economic impact adrenaline ISRCTN73485024  Registered 13 March 2014",
        "mesh_terms": [
            "Adult",
            "Aged",
            "Cost-Benefit Analysis",
            "Epinephrine",
            "Female",
            "Humans",
            "Male",
            "Middle Aged",
            "Out-of-Hospital Cardiac Arrest",
            "Quality-Adjusted Life Years"
        ],
        "source": "https://pubmed.ncbi.nlm.nih.gov/32981529/",
        "source_type": "Bangladesh-specific"
    },
    {
        "pmid": "32925910",
        "title": "Wide range of G6PD activities found among ethnic groups of the Chittagong Hill Tracts, Bangladesh.",
        "abstract": "proportion Plasmodium vivax malaria among malaria increasing worldwide Treatment 8aminoquinolines remain radical cure However 8aminoquinolines cause severe hemolysis glucose6phosphate dehydrogenase G6PD deficient patients population multiethnic Chittagong Hill Tracts CHT carry highest malaria burden within Bangladesh many country national treatment guideline recommend 8aminoquinoline based radical cure without routine G6PD deficiency G6PDd testing guide treatment Aim study determine need routine testing within multiethnic population assessing prevalence G6PDd among local population Participants 11 ethnicity randomly selected malaria status assessed microscopy rapid diagnostic test RDT polymerase chain reaction PCR G6PD status determined spectrophotometry G6PD genotyping adjusted male median AMM defined 100 G6PD activity participant categorized G6PD deficient 30 activity G6PD intermediate 30 70 activity G6PD normal 70 activity Median G6PD activity ethnicity compared association G6PD activity malaria status assessed 1002 participant enrolled tested malaria G6PD activity measured spectrophotometry 999 participant host G6PD genotyping undertaken 323 participants Seven participant 07 peripheral parasitaemia detected microscopy RDT 42 PCR 42 Among 106 participant 328 confirmed genotype 99 934 Mahidol variant AMM 703UgHb 90 90 G6PD deficient participant 133 133 intermediate G6PD activity Median G6PD activity differed significantly ethnicity p0001 proportion G6PD deficient individual ranged 2 26 differ participant without malaria high G6PDd prevalence significant variation ethnicity suggest routine G6PDd testing guide 8aminoquinoline based radical CHT comparable settings",
        "mesh_terms": [
            "Adult",
            "Aminoquinolines",
            "Bangladesh",
            "Diagnostic Tests, Routine",
            "Ethnicity",
            "Female",
            "Glucosephosphate Dehydrogenase",
            "Glucosephosphate Dehydrogenase Deficiency",
            "Humans",
            "Malaria, Vivax",
            "Male",
            "Middle Aged",
            "Polymerase Chain Reaction",
            "Prevalence",
            "Young Adult"
        ],
        "source": "https://pubmed.ncbi.nlm.nih.gov/32925910/",
        "source_type": "Bangladesh-specific"
    },
    {
        "pmid": "32718342",
        "title": "Implementing parasite genotyping into national surveillance frameworks: feedback from control programmes and researchers in the Asia-Pacific region.",
        "abstract": "AsiaPacific region face formidable challenge achieving malaria elimination proposed target 2030 Molecular surveillance Plasmodium parasite provide important information malaria transmission adaptation inform national malaria control programme NMCPs decisionmaking processes November 2019 parasite genotyping workshop held Jakarta Indonesia review molecular approach parasite surveillance explore way tool integrated public health system inform policy meeting attended 70 participant 8 malariaendemic country partner Asia Pacific Malaria Elimination Network participant acknowledged utility multiple use case parasite genotyping including quantifying prevalence drug resistant parasites predicting risk treatment failure identifying major route reservoir infection monitoring imported malaria contribution local transmission characterizing origin dynamic malaria outbreaks estimating frequency Plasmodium vivax relapses However priority use case varies different endemic settings Although onesizefitsall approach molecular surveillance unlikely applicable across AsiaPacific region consensus spectrum addedvalue activity help support data sharing across national boundaries Knowledge exchange needed establish local expertise different laboratorybased methodology bioinformatics processes Collaborative research involving local international team help maximize impact analytical output operational need NMCPs Research also needed explore costeffectiveness genetic epidemiology different use case help leverage funding widescale implementation Engagement NMCPs local researcher critical throughout process",
        "mesh_terms": [
            "Asia",
            "Congresses as Topic",
            "Epidemiological Monitoring",
            "Feedback",
            "Genotype",
            "Malaria, Falciparum",
            "Malaria, Vivax",
            "Pacific Islands",
            "Plasmodium falciparum",
            "Plasmodium vivax",
            "Population Surveillance"
        ],
        "source": "https://pubmed.ncbi.nlm.nih.gov/32718342/",
        "source_type": "Bangladesh-specific"
    },
    {
        "pmid": "32718336",
        "title": "Cost-effectiveness of inhaled oxytocin for prevention of postpartum haemorrhage: a modelling study applied to two high burden settings.",
        "abstract": "Access oxytocin prevention postpartum haemorrhage PPH resourcepoor setting limited requirement consistent cold chain skilled attendant administer injection overcome barriers heatstable noninjectable formulation oxytocin development including oxytocin inhalation study modelled costeffectiveness inhaled oxytocin product IHO Bangladesh Ethiopia decision analytic model developed assess costeffectiveness IHO prevention PPH compared standard care Bangladesh Ethiopia Bangladesh introduction IHO modelled public facility home delivery without skilled attendant Ethiopia IHO modelled public facility home delivery health extension workers Costs costs introduction PPH prevention PPH treatment effect PPH case averted death averted modelled 12month program Life year gained modelled lifetime horizon discounted 3 Cost maintaining cold chain effect compromised oxytocin quality in absence cold chain modelled Bangladesh IHO estimated avert 18644 case PPH 76 maternal death 1954 maternal life year lost also yielded costsaving majority gain occurring among home delivery IHO would replace misoprostol Ethiopia IHO averted 3111 PPH cases 30 maternal death 767 maternal life year lost full IHO introduction program bear incremental costeffectiveness ratio ICER 2 3 time percapita Gross Domestic Product GDP 1880 USD per maternal life year lost thus unlikely considered costeffective Ethiopia However ICER routine IHO administration considering recurring cost alone fall 25 percapita GDP 175 USD per maternal lifeyear saved IHO potential expand access uterotonics reduce PPHassociated morbidity mortality high burden settings facilitate reduced spending PPH management making product highly costeffective setting coverage institutional delivery lagging",
        "mesh_terms": [
            "Adolescent",
            "Adult",
            "Bangladesh",
            "Cost-Benefit Analysis",
            "Ethiopia",
            "Female",
            "Humans",
            "Middle Aged",
            "Oxytocin",
            "Postpartum Hemorrhage",
            "Pregnancy",
            "Respiratory Therapy",
            "Young Adult"
        ],
        "source": "https://pubmed.ncbi.nlm.nih.gov/32718336/",
        "source_type": "Bangladesh-specific"
    },
    {
        "pmid": "32690512",
        "title": "Estimation of total cardiovascular risk using the 2019 WHO CVD prediction charts and comparison of population-level costs based on alternative drug therapy guidelines: a population-based study of adults in Bangladesh.",
        "abstract": "objective study estimate population distribution 10year cardiovascular disease CVD risk among Bangladeshi adult aged 40 year above using 2019 CVD risk prediction charts Additionally compared cost CVD pharmacological treatment based total CVD risk thresholds ≥30≥20 single risk factor hypertension cutoff level Bangladeshi context Crosssectional populationbased study 2013 2014 collected data nationally representative crosssectional survey adult aged ≥40 year urban rural area Bangladesh n6189 estimated CVD risk using 2019 CVD risk prediction chart categorised low 5 low 5 10 moderate 10 20 high 20 30 high risk ≥30 estimated drug therapy cost using lowest price drug class available aspirin thiazide diuretics statin ACE inhibitors compared total cost drug therapy using total CVD risk versus single risk factor approach primary outcome 10year CVD risk categorised low 5 low 5 10 moderate 10 20 high 20 30 high risk ≥30 majority adult 852 95 CI 843 861 10year CVD risk less 10 proportion adult 10year CVD risk ≥20 051 one adult categorised 10year CVD risk ≥30 Among adult CVD risk group low low moderate 174 279 414 hypertension blood pressure BP ≥14090 01 17 29 severe hypertension BP ≥160100 respectively Using total CVD risk approach would reduce drug cost per million population US144 540 risk ≥20 reduce healthcare expenditure prevention treatment CVD total risk approach using 2019 CVD risk prediction chart may lead cost savings",
        "mesh_terms": [
            "Adult",
            "Aged",
            "Bangladesh",
            "Cardiovascular Diseases",
            "Cross-Sectional Studies",
            "Drug Costs",
            "Female",
            "Heart Disease Risk Factors",
            "Humans",
            "Hypertension",
            "Male",
            "Middle Aged",
            "Risk Assessment"
        ],
        "source": "https://pubmed.ncbi.nlm.nih.gov/32690512/",
        "source_type": "Bangladesh-specific"
    },
    {
        "pmid": "32669092",
        "title": "What contributes to inappropriate antibiotic dispensing among qualified and unqualified healthcare providers in Bangladesh? A qualitative study.",
        "abstract": "Overprescribing inappropriate use antibiotic contributes emergence antimicrobial resistance AMR study low middleincome setting employed qualitative approach examine driver antibiotic sale dispensing across full range healthcare provider HCPs aimed explore understanding use function antibiotics awareness AMR perceived patient customer demand adherence among HCPs human animal medicine Bangladesh used ethnographic approach conduct facetoface indepth interview 46 community HCPs one urban one rural area Gazipur Mirzapur district respectively purposefully selected participant four category provider human veterinary medicine qualified semiqualified auxiliary unqualified Using grounded theory approach thematic analysis conducted using framework method Antibiotics considered medicine power give quick result work almost diseases including viruses price antibiotic equated power expensive antibiotic considered powerful medicines Antibiotics also seen preventative medicines provider well informed antibiotic resistance causes others completely unaware Many provider mistook antibiotic resistance side effect antibiotics human animal medicine Despite varied knowledge provider showed concern antibiotic resistance responsibility inappropriate antibiotic use shifted patient client including owner livestock animals Misconceptions misinformation led wide range inappropriate us antibiotic across different category human animal healthcare providers Low awareness antibiotic action antibiotic resistance apparent among healthcare providers particularly little training rural areas Specific targeted intervention address AMR Bangladesh include educational message rational use antibiotic work targeting type healthcare providers tailored training provider may increase understanding antibiotic action improve practices farreaching structural change required influence increase responsibility optimising antibiotic dispensing among HCPs",
        "mesh_terms": [
            "Anti-Bacterial Agents",
            "Antimicrobial Stewardship",
            "Bangladesh",
            "Clinical Competence",
            "Community Health Workers",
            "Drug Resistance, Microbial",
            "Drug Utilization",
            "Health Knowledge, Attitudes, Practice",
            "Health Personnel",
            "Humans",
            "Inappropriate Prescribing",
            "Interviews as Topic",
            "Nonprescription Drugs",
            "Prescription Drugs",
            "Qualitative Research"
        ],
        "source": "https://pubmed.ncbi.nlm.nih.gov/32669092/",
        "source_type": "Bangladesh-specific"
    },
    {
        "pmid": "32542043",
        "title": "Healthcare seeking for chronic illness among adult slum dwellers in Bangladesh: A descriptive cross-sectional study in two urban settings.",
        "abstract": "Accompanying rapid urbanization Bangladesh inequity health healthcare visibly manifested slum lowincome settlements study examines socioeconomic demographic geographic pattern selfreported chronic illness healthcare seeking among adult slum dweller Bangladesh Understanding pattern critical designing equitable urban health system enabling countrys goal Universal Health Coverage 2030 descriptive crosssectional study compare survey data slum settlement located two urban site Bangladesh Tongi Sylhet Reported chronic illness symptom associated healthcareseeking strategy compared catastrophic impact household healthcare expenditure assessed Significant difference healthcareseeking chronic illness apparent within slum settlement related sex wealth score PPI location Women likely use private clinic men Compared poorer residents wealthier household sought care greater extent private clinics poorer household relied drug shop public hospitals Chronic symptom also differed greater prevalence musculoskeletal respiratory digestive neurological symptom reported among lower PPIs slum sites reliance private healthcare market widespread greater industrialized Tongi Tongi also experienced higher probability catastrophic expenditure Sylhet Study result point value understanding contextspecific healthseeking pattern chronic illness designing delivery strategy address growing burden NCDs slum environments Slums complex social geographic entity cannot generalized Priority attention focused developing chronic care service meet need working poor term proximity opening hours quality cost",
        "mesh_terms": [
            "Adult",
            "Bangladesh",
            "Chronic Disease",
            "Cross-Sectional Studies",
            "Female",
            "Geography",
            "Health Expenditures",
            "Health Services Needs and Demand",
            "Humans",
            "Male",
            "Patient Acceptance of Health Care",
            "Poverty",
            "Quality of Health Care",
            "Urban Health Services",
            "Urban Population",
            "Urbanization"
        ],
        "source": "https://pubmed.ncbi.nlm.nih.gov/32542043/",
        "source_type": "Bangladesh-specific"
    },
    {
        "pmid": "32431267",
        "title": "The WorldWide Antimalarial Resistance Network Clinical Trials Publication Library: A Live, Open-Access Database of <i>Plasmodium</i> Treatment Efficacy Trials.",
        "abstract": "Parasite resistance antimalarial drug pose serious threat malaria control WorldWide Antimalarial Resistance Network WWARN aim provide collaborative platform support global malaria research effort Here describe WWARN clinical trial publication library openaccess uptodate resource streamline synthesis antimalarial safety efficacy data series iteratively refined database search conducted identify prospective clinical trial assessing antimalarial drug efficacy least 28 day followup approximately 45000 article screened 1221 trial published 1946 2018 identified representing 2339 treatment arm 323819 patients trial endemic locations 757 7871040 recruited patient iPlasmodium falciparumi 170 1771040 iPlasmodium vivaxi 69 721040 both 04 41040 iPlasmodiumi species 572 5851022 trial included underfives 53 551036 included pregnant women Africa marked increase iP falciparumi iP vivaxi study last two decades WHOrecommended artemisininbased combination therapy alone gametocidal drug assessed 395 7051783 iP falciparumi treatment arm 105 45429 iP vivaxi arms increasing 780 266341 229 27118 respectively last five years library comprehensive openaccess tool used malaria community explore collective knowledge antimalarial efficacy available httpswwwwwarnorgtoolsresourcesliteraturereviewswwarnclinicaltrialspublicationlibrary first kind field global infectious diseases lesson learnt creation adapted infectious diseases",
        "mesh_terms": [
            "Antimalarials",
            "Clinical Trials as Topic",
            "Databases, Bibliographic",
            "Databases, Factual",
            "Drug Resistance",
            "Drug Therapy, Combination",
            "Humans",
            "Malaria",
            "Malaria, Falciparum",
            "Malaria, Vivax",
            "Plasmodium",
            "Plasmodium falciparum",
            "Plasmodium knowlesi",
            "Plasmodium malariae",
            "Plasmodium ovale",
            "Plasmodium vivax"
        ],
        "source": "https://pubmed.ncbi.nlm.nih.gov/32431267/",
        "source_type": "Bangladesh-specific"
    },
    {
        "pmid": "32407380",
        "title": "Quantification of glucose-6-phosphate dehydrogenase activity by spectrophotometry: A systematic review and meta-analysis.",
        "abstract": "radical cure Plasmodium vivax P ovale requires treatment primaquine tafenoquine clear dormant liver stages Either drug induce haemolysis individual glucose6phosphate dehydrogenase G6PD deficiency necessitating screening reference diagnostic method G6PD activity ultraviolet UV spectrophotometry however universal G6PD activity threshold drug safely administered yet defined study aimed quantify assaybased variation G6PD spectrophotometry explore diagnostic implication applying universal threshold Individuallevel data pooled study used G6PD spectrophotometry Studies identified via PubMed search 25 April 2018 unpublished contribution contacted author PROSPERO CRD42019121414 Studies excluded assessed individual known haematological conditions family studies insufficient details Studies malaria patient included analysed separately Included study assessed risk bias using adapted form Quality Assessment Diagnostic Accuracy Studies2 QUADAS2 tool Repeatability intra interlaboratory variability G6PD activity measurement compared study pooled across dataset universal threshold G6PD deficiency derived diagnostic performance compared sitespecific thresholds Study participant n  15811 aged 0 86 years 444 7083 women Median range activity G6PD normal G6PDn control sample 100 Ug Hb 63140 Trinity assay 83 Ug Hb 68156 Randox assay G6PD activity distribution varied significantly studies 13 study used Trinity assay adjusted male median AMM standardised metric 100 G6PD activity varied 57 126 Ug Hb p  0001 Assay precision varied laboratories assessed variance control measurement from 01 15 Ug Hb p  0001 studywise mean coefficient variation CV replicate measure from 16 149 p  0001 universal threshold 100 G6PD activity defined 94 Ug Hb yielding diagnostic threshold 66 Ug Hb 70 activity 28 Ug Hb 30 activity threshold diagnosed individual less 30 G6PD activity studywise sensitivity 89 95 CI 8194 100 95 CI 96100 specificity 96 95 CI 8999 100 100100 However considering intermediate deficiency 70 G6PD activity sensitivity fell minimum 64 95 CI 5275 specificity 35 95 CI 2446 ability identify underlying factor associated studylevel heterogeneity limited lack availability covariate data diverse study context methodologies finding indicate substantial variation G6PD measurement spectrophotometry sites likely due variability laboratory methods possible contribution unmeasured population factors assayspecific universal quantitative threshold offer robust diagnosis 30 level interstudy variability impedes performance universal threshold 70 level Caution advised comparing finding based absolute G6PD activity measurement across studies Novel handheld quantitative G6PD diagnostics may allow greater standardisation future",
        "mesh_terms": [
            "Adolescent",
            "Adult",
            "Aged",
            "Aged, 80 and over",
            "Antimalarials",
            "Child",
            "Child, Preschool",
            "Female",
            "Glucosephosphate Dehydrogenase",
            "Glucosephosphate Dehydrogenase Deficiency",
            "Humans",
            "Infant",
            "Infant, Newborn",
            "Malaria",
            "Male",
            "Middle Aged",
            "Spectrophotometry",
            "Young Adult"
        ],
        "source": "https://pubmed.ncbi.nlm.nih.gov/32407380/",
        "source_type": "Bangladesh-specific"
    },
    {
        "pmid": "32405422",
        "title": "Review of safety and minimum pricing of nitazoxanide for potential treatment of COVID-19.",
        "abstract": "Many treatment assessed repurposing treat coronavirus disease 2019 COVID19 One drug shown promising result iin vitroi nitazoxanide Unlike postulated drugs nitazoxanide show high ratio maximum plasma concentration Csubmaxsub 1 day 500 mg twice daily BD concentration required inhibit 50 replication ECsub50sub severe acute respiratory syndrome coronavirus 2 SARSCoV2 Csubmax sub ECsub50sub roughly equal 141 such important investigate safety nitazoxanide trials Furthermore treatment COVID19 cheap promote global access price many drug far higher cost production aimed conduct review safety nitazoxanide prior indication calculate minimum cost production review nitazoxanide clinical research conducted using EMBASE MEDLINE databases supplemented ClinicalTrialsgov searched phase 2 3 randomised controlled trial RCTs comparing nitazoxanide placebo active control 514 day participant experiencing acute infection kind Data extracted grade 14 serious adverse event AEs Data also extracted gastrointestinal GI AEs well hepatorenal cardiovascular effectsActive pharmaceutical ingredient cost data 2016 2019 extracted Panjiva database adjusted 5 loss production cost excipients formulation 10 profit margin tax Two dosages 500 mg BD higher dose 1100 mg three time daily TDS considered estimated cost compared publicly available list price selection countries Nine RCTs nitazoxanide identified inclusion RCTs accounted 1514 participant estimated 953 personyearsoffollowup significant difference found AE endpoint assessed across trial subgroup analysis active placebocontrolled trials Mild GI AEs increased dose hepatorenal cardiovascular concern raised appropriate metric reported teratogenic concerns evidence base limitedBased weightedmean cost US 61kg 14day course treatment nitazoxanide 500 mg BD would cost 141 daily cost would therefore 010 14day course could cost 3944 US commercial pharmacies 3 per course Pakistan India Bangladesh higher dose 1100 mg TDS estimated cost 408 per 14day course equivalent 029 per day Nitazoxanide demonstrates good safety profile approved doses However evidence required regarding hepatorenal cardiovascular effects well teratogenicity estimate would possible manufacture nitazoxanide generic 141 14day treatment course 500 mg BD 408 1100 mg TDS trial COVID19 patient initiated efficacy SARSCoV2 demonstrated clinical studies nitazoxanide may represent safe affordable treatment ongoing pandemic",
        "mesh_terms": [],
        "source": "https://pubmed.ncbi.nlm.nih.gov/32405422/",
        "source_type": "Bangladesh-specific"
    },
    {
        "pmid": "32332142",
        "title": "Global injury morbidity and mortality from 1990 to 2017: results from the Global Burden of Disease Study 2017.",
        "abstract": "Past research population health trend shown injury form substantial burden population health loss Regular update injury burden assessment critical report Global Burden Disease GBD 2017 Study estimate morbidity mortality injuries reviewed result injury GBD 2017 study GBD 2017 measured injuryspecific mortality year life lost YLLs using Cause Death Ensemble model measure nonfatal injuries GBD 2017 modelled injuryspecific incidence converted prevalence year lived disability YLDs YLLs YLDs summed calculate disabilityadjusted life year DALYs 1990 4 260 493 4 085 700 4 396 138 injury deaths increased 4 484 722 4 332 010 4 585 554 death 2017 agestandardised mortality decreased 1079 1073 1086 738 730 745 per 100 000 1990 354 064 302 95 uncertainty interval 338 174 876 371 610 802 new case injury globally increased 520 710 288 493 430 247 547 988 635 new case 2017 time agestandardised incidence decreased nonsignificantly 6824 6534 7147 6763 6412 7118 per 100 000 1990 2017 agestandardised DALYs decreased 4947 4655 5233 per 100 000 3267 3058 3505 Injuries important cause health loss globally though mortality declined 1990 2017 Future research injury burden focus prevention highburden populations improving data collection ensuring access medical care",
        "mesh_terms": [
            "Global Burden of Disease",
            "Global Health",
            "Humans",
            "Incidence",
            "Life Expectancy",
            "Morbidity",
            "Quality-Adjusted Life Years",
            "Wounds and Injuries"
        ],
        "source": "https://pubmed.ncbi.nlm.nih.gov/32332142/",
        "source_type": "Bangladesh-specific"
    },
    {
        "pmid": "32094104",
        "title": "The effect of doxofylline in asthma and COPD.",
        "abstract": "Theophylline still one widely prescribed drug treatment asthma COPD developing country majority asthma COPD medicine largely unavailable also cheap option case antiinflammatory effect capacity reverse corticosteroid resistance deserve consideration induce numerous side effect drugdrug interaction frequently requires measurement drug level plasma order overcome problem posed theophylline xanthine developed Doxofylline newer generation xanthine bronchodilating antiinflammatory activity reason called novofylline differs substantially theophylline pharmacological level Clinical study shown substantial difference doxofylline theophylline particular efficacysafety profile doxofylline better theophylline",
        "mesh_terms": [
            "Anti-Inflammatory Agents",
            "Asthma",
            "Bronchodilator Agents",
            "Drug Costs",
            "Economics, Pharmaceutical",
            "Female",
            "Humans",
            "Male",
            "Pulmonary Disease, Chronic Obstructive",
            "Theophylline",
            "Treatment Outcome"
        ],
        "source": "https://pubmed.ncbi.nlm.nih.gov/32094104/",
        "source_type": "Bangladesh-specific"
    },
    {
        "pmid": "32074419",
        "title": "A Community-Based Intervention for Managing Hypertension in Rural South Asia.",
        "abstract": "burden hypertension escalating control rate poor low middleincome countries Cardiovascular mortality high rural areas conducted clusterrandomized controlled trial rural district Bangladesh Pakistan Sri Lanka total 30 community randomly assigned either multicomponent intervention intervention group usual care control group intervention involved home visit trained government community health worker bloodpressure monitoring counseling training physicians care coordination public sector total 2645 adult hypertension enrolled primary outcome reduction systolic blood pressure 24 months Followup 24 month completed 90 participants baseline mean systolic blood pressure 1467 mm Hg intervention group 1447 mm Hg control group 24 months mean systolic blood pressure fell 90 mm Hg intervention group 39 mm Hg control group mean reduction 52 mm Hg greater intervention 95 confidence interval CI 32 71 P0001 mean reduction diastolic blood pressure 28 mm Hg greater intervention group control group 95 CI 17 39 Bloodpressure control 14090 mm Hg achieved 532 participant intervention group compared 437 control group relative risk 122 95 CI 110 135 Allcause mortality 29 intervention group 43 control group rural community Bangladesh Pakistan Sri Lanka multicomponent intervention centered proactive home visit trained government community health worker linked existing public health care infrastructure led greater reduction blood pressure usual care among adult hypertension Funded Joint Global Health Trials scheme COBRABPS ClinicalTrialsgov number NCT02657746",
        "mesh_terms": [
            "Aged",
            "Antihypertensive Agents",
            "Asia, Western",
            "Blood Pressure",
            "Blood Pressure Determination",
            "Checklist",
            "Community Health Workers",
            "Developing Countries",
            "Education, Medical, Continuing",
            "Female",
            "Health Care Costs",
            "House Calls",
            "Humans",
            "Hypertension",
            "Male",
            "Middle Aged",
            "Patient Education as Topic",
            "Public Health Practice",
            "Rural Population"
        ],
        "source": "https://pubmed.ncbi.nlm.nih.gov/32074419/",
        "source_type": "Bangladesh-specific"
    },
    {
        "pmid": "31915349",
        "title": "Nitrous Oxide versus Medical Air Using in General Anaesthesia During Laparoscopic Cholecystectomy: A Comparative Study.",
        "abstract": "study designed observe haemodynamic changes recovery status cost effectiveness anaesthesia laparoscopic cholecystectomy medical air comparison anaesthesia nitrous oxide associated maintain adequate analgesia conducted department Analgesia Intensive Care Medicine Bangabandhu Sheikh Mujib Medical University BSMMU Dhaka Bangladesh January 2017 June 2017 Nitrous oxide popularly using analgesic current balanced general anesthesia addition carrier agent anesthetic Intraoperative pain intensity depends many variable including type surgery surgical stimulation surgical incision difficult measure intraoperative pain properly general anesthesia therefore anesthetist depends surrogate marker inadequate analgesia like raised heart rate blood pressure sweating lacrimation However unfortunately parameter may change direction light plane anesthesia hypercarbia ongoing procedural status patient",
        "mesh_terms": [
            "Analgesics",
            "Anesthesia",
            "Anesthesia Recovery Period",
            "Anesthesia, General",
            "Bangladesh",
            "Cholecystectomy, Laparoscopic",
            "Cholelithiasis",
            "Cost-Benefit Analysis",
            "Hemodynamics",
            "Humans",
            "Monitoring, Intraoperative",
            "Nitrous Oxide",
            "Postoperative Period"
        ],
        "source": "https://pubmed.ncbi.nlm.nih.gov/31915349/",
        "source_type": "Bangladesh-specific"
    },
    {
        "pmid": "31915273",
        "title": "Burden of injury along the development spectrum: associations between the Socio-demographic Index and disability-adjusted life year estimates from the Global Burden of Disease Study 2017.",
        "abstract": "epidemiological transition noncommunicable disease replacing infectious disease main contributor disease burden well documented global health literature Less focus however given relationship sociodemographic change injury aim study examine association disabilityadjusted life year DALYs injury 195 country territory different level along development spectrum 1990 2017 based Global Burden Disease GBD 2017 estimates Injury mortality estimated using GBD mortality database correction garbage coding CODEmthe cause death ensemble modelling tool Morbidity estimation based survey inpatient outpatient data set 30 causeofinjury 47 natureofinjury category each Sociodemographic Index SDI composite indicator includes lagged income per capita average educational attainment age 15 year total fertility rate many cause injury agestandardised DALY rate declined increasing SDI although road injury interpersonal violence selfharm follow pattern Particularly selfharm opposing pattern observed region similar SDI levels road injuries effect less pronounced overall global pattern declining injury burden increasing SDI However injury follow pattern suggests multiple underlying mechanism influencing injury DALYs need detailed understanding pattern help inform national global effort address injuryrelated health outcome across development spectrum",
        "mesh_terms": [
            "Adolescent",
            "Persons with Disabilities",
            "Global Burden of Disease",
            "Global Health",
            "Humans",
            "Life Expectancy",
            "Quality-Adjusted Life Years",
            "Wounds and Injuries"
        ],
        "source": "https://pubmed.ncbi.nlm.nih.gov/31915273/",
        "source_type": "Bangladesh-specific"
    },
    {
        "pmid": "31752841",
        "title": "Antenatal care in rural Bangladesh: current state of costs, content and recommendations for effective service delivery.",
        "abstract": "Measurement antenatal care ANC service coverage often limited number contact type providers reflecting gap assessment quality well cost estimation health impact study aim determine service subcomponents provider patient cost ANC service compare community ie satellite clinics facility care ie primary secondary health centers setting rural Bangladesh Service content cost data collected one researcher four interviewer various community facility health care setting Gaibandha district September December 2016 conducted structured interview organization managers observational study ANC service provision n  70 service content provider cost service drug costs exit interview pregnant woman n  70 patient cost direct indirect costs health clinic community facility levels Fishers exact test used determine different patient characteristic community facility settings ANC service content assessed 63 subitems categorized 11 group compared within across community facility settings Provider patient cost collected Bangladesh taka analyzed 2016 US Dollars 0013 exchange rate found generally similar provider patient characteristic community facility setting except clients gestational age High compliance  50 service subcomponents observed blood pressure monitoring weight measurement iron folate supplementation given tetanus vaccine lower compliance service subcomponents  50 observed physical examination edema ultrasonogram routine test blood test urine test Average unit cost ANC service provision double facility level 275 compared communitybased care 162 ANC patient cost facility 266 three time higher community 078 study reveals delay pregnant womens initial ANC care seeking gap compliance ANC subcomponents difference provider patient cost facility community settings",
        "mesh_terms": [
            "Bangladesh",
            "Female",
            "Health Care Costs",
            "Health Services Research",
            "Humans",
            "Pregnancy",
            "Prenatal Care",
            "Rural Health Services"
        ],
        "source": "https://pubmed.ncbi.nlm.nih.gov/31752841/",
        "source_type": "Bangladesh-specific"
    },
    {
        "pmid": "31706178",
        "title": "Comparative Analysis of Prescription Drug Prices in South Asian Association for Regional Cooperation Countries.",
        "abstract": "SAARC South Asian Association Regional Cooperation geopolitical organization composed 8 neighboring countries Afghanistan Bangladesh Bhutan India Maldives Nepal Pakistan Sri Lanka objective study compare price selected drug SAARC countries list 24 drug prepared based certain inclusion exclusion criteria retail price drug determined different source verified manually open market price obtained local currency converted US dollar comparison purposes another analysis gross domestic product GDP country factored comparative analysis 23 drugs 17 comparison across country statistically different P  05 analysis revealed large difference drug price among SAARC countries GDPadjusted median drug price revealed polarized picture Nepal generally highest price 19 24 drugs Sri Lanka lowest 19 24 drugs example widely used antipsychotic drug risperidone 7 time expensive Pakistan 0316 compared Sri Lanka 0045 Adjusting GDP made risperidone 18 time expensive 2190 120 across 2 countries Prices selected drug varied markedly SAARC countries adjusting GDP drug price became polarized across countries Nepal featuring highest prices determining drug prices countrys GDP populations purchasing power need taken account",
        "mesh_terms": [
            "Afghanistan",
            "Analysis of Variance",
            "Asia, Southeastern",
            "Bangladesh",
            "Bhutan",
            "Cooperative Behavior",
            "Costs and Cost Analysis",
            "Humans",
            "India",
            "Indian Ocean Islands",
            "Nepal",
            "Pakistan",
            "Prescription Drugs",
            "Sri Lanka"
        ],
        "source": "https://pubmed.ncbi.nlm.nih.gov/31706178/",
        "source_type": "Bangladesh-specific"
    },
    {
        "pmid": "31699941",
        "title": "The Threat of Emerging and Re-emerging Infections in Indonesia.",
        "abstract": "Human immunodeficiency virus HIV one example emerging infection total 386 district province Indonesia reported infection cumulative number HIV infected patient year 1987 2014 150296 AIDS 55799 patients access care available 153887 patient among HIVAIDS patient 70 eligible antiretroviral ARV treatment half adhered ARV treatment addition that increased risk emerging disease Zika virus Monkey pox Hanta pulmonary syndrome since sporadic case reported around regionBeside new diseases tuberculosis dengue virus malaria diphteria continuously reported Indonesia classified reemerging illnesses edition data diphteria epidemiology Indonesia shown Karyanti et al6 recent outbreak diphteria Indonesia involved almost province country led response named ORI outbreak response Immunization Regardless immunization proper treatment including distribution antitoxin antibiotic needed stop spread particular bacteria decreasing mortality rate conclusion author paper mentioned immunization gap need handle systematically Immunization data released 2017 showed complete immunization given 20 targeted group almost 75 either unvaccinated unknown outbreak diphteria Indonesia also reported several country similar problem Bangladesh Haiti Yamen shown coordination doctor clinichospital public health officer conduct epidemiological investigation conjunction giving prophylaxis assuring logistics antidiphteria toxin antibiotic accessible key success eliminating diphteria like BangladeshAdherence treatment multifactorial illnesses First duration treatment potential adverse event due medication Ministry Health Republic Indonesia support early diagnosis HIV delivering treatment soon possible order avoid transmission disease Second looking another side story HIV infected patients receiving ARV treatment long life treatment could possibly cause adverse event somewhere along line Budiman etal reported factor might contribute liver injury study show measuring baseline liver function test AST routinely might minimize toxicity ARV patient particularly low body mass index Last despite adherence treatment procedure minimizing risk adverse event medication facing primary resistance virus transmitted community mentioned Megasari et al8 report regarding transmission drug resistance HIV virus naïve patient BaliThe Indonesian government Indonesian Ministry Health established collaboration one health approach tackle threat disease country particularly infectious diseases",
        "mesh_terms": [
            "Communicable Diseases, Emerging",
            "Cost of Illness",
            "Diphtheria",
            "HIV Infections",
            "Humans",
            "Indonesia",
            "Tuberculosis"
        ],
        "source": "https://pubmed.ncbi.nlm.nih.gov/31699941/",
        "source_type": "Bangladesh-specific"
    },
    {
        "pmid": "31648271",
        "title": "Economic evaluation of community acquired pneumonia management strategies: A systematic review of literature.",
        "abstract": "Communityacquired pneumonia CAP major cause mortality morbidity worldwide Efficient use resource fundamental best use money among available novel treatment option management pneumonia objective study systematically review economic analysis management strategy pneumonia systematic search performed using Academic Search Complete MEDLINE EconLit Global health MEDLINE complete Embase database using specific subject heading key word May 2018 without restricting publication year search result recorded type economic evaluation management CAP included detailed review Consolidated Health Economic Evaluation Reporting Standards CHEERS checklist used quality appraisal Nineteen study met inclusion criteria ten study trial based five conducted analysis using model based technique rest study either based observational record review prepost intervention studies study conducted costeffectiveness analysis n  15 compared different combination antimicrobials based developed country n  17 considered adult age group n  16 used provider perspective n  14 Nine study reported dominant alternative lower cost higher benefit Sensitivity analysis performed majority study n  15 Fourteen study assessed either excellent good good quality relationship found publication year study quality Methodological variation type microbial used perspective cost outcome measure limit compatibility among result included studies Economic evaluation intervention management CAP date support costeffectiveness studied interventions However evidence relates largely antimicrobial choice older population developed countries Parallel economic evaluation different management strategy CAP recommended developed developing country support rigorous robust comparative economic analysis within health care systems PROSPERO registration no CRD42018097174",
        "mesh_terms": [
            "Anti-Bacterial Agents",
            "Community-Acquired Infections",
            "Cost-Benefit Analysis",
            "Delivery of Health Care",
            "Disease Management",
            "Humans",
            "Pneumonia",
            "Quality-Adjusted Life Years"
        ],
        "source": "https://pubmed.ncbi.nlm.nih.gov/31648271/",
        "source_type": "Bangladesh-specific"
    },
    {
        "pmid": "31645575",
        "title": "Acetic acid: a cost-effective agent for mitigation of seawater-induced salt toxicity in mung bean.",
        "abstract": "current study sought effective mitigation measure seawaterinduced damage mung bean plant exploring potential role acetic acid AA Principal component analysis PCA revealed foliar application AA control condition improved mung bean growth interlinked enhanced level photosynthetic rate pigments improved water status increased uptake Ksupsup comparison watersprayed control Mung bean plant exposed salinity exhibited reduced growth biomass production emphatically correlated increased accumulation Nasupsup reactive oxygen specie malondialdehyde impaired photosynthesis evidenced PCA heatmap clustering AA supplementation ameliorated toxic effect seawater improved growth performance salinityexposed mung bean AA potentiated several physiobiochemical mechanism connected increased uptake Casup2sup Mgsup2sup reduced accumulation toxic Nasupsup improved water use efficiency enhanced accumulation proline total free amino acid soluble sugars increased catalase activity heightened level phenolic flavonoids Collectively result provided new insight AAmediated protective mechanism salinity mung bean thereby proposing AA potential costeffective chemical management saltinduced toxicity mung bean perhaps cash crops",
        "mesh_terms": [
            "Acetic Acid",
            "Biomass",
            "Cost-Benefit Analysis",
            "Gases",
            "Minerals",
            "Osmosis",
            "Oxidative Stress",
            "Phenotype",
            "Photosynthesis",
            "Pigments, Biological",
            "Plant Leaves",
            "Plant Stomata",
            "Plant Transpiration",
            "Potassium",
            "Principal Component Analysis",
            "Reactive Oxygen Species",
            "Salinity",
            "Seawater",
            "Sodium",
            "Vigna",
            "Water"
        ],
        "source": "https://pubmed.ncbi.nlm.nih.gov/31645575/",
        "source_type": "Bangladesh-specific"
    },
    {
        "pmid": "31560378",
        "title": "Global, Regional, and National Cancer Incidence, Mortality, Years of Life Lost, Years Lived With Disability, and Disability-Adjusted Life-Years for 29 Cancer Groups, 1990 to 2017: A Systematic Analysis for the Global Burden of Disease Study.",
        "abstract": "Cancer noncommunicable disease NCDs widely recognized threat global development latest United Nations highlevel meeting NCDs reaffirmed observation also highlighted slow progress meeting 2011 Political Declaration Prevention Control Noncommunicable Diseases third Sustainable Development Goal Lack situational analyses priority setting budgeting identified major obstacle achieving goals common require information local cancer epidemiology Global Burden Disease GBD study uniquely poised provide crucial data describe cancer burden 29 cancer group 195 country 1990 2017 provide data needed cancer control planning used GBD study estimation method describe cancer incidence mortality year lived disability year life lost disabilityadjusted lifeyears DALYs Results presented national level well Sociodemographic Index SDI composite indicator income educational attainment total fertility rate also analyzed influence epidemiological v demographic transition cancer incidence 2017 245 million incident cancer case worldwide 168 million without nonmelanoma skin cancer NMSC 96 million cancer deaths majority cancer DALYs came year life lost 97 3 came year lived disability odds developing cancer lowest low SDI quintile 1 7 highest high SDI quintile 1 2 sexes 2017 common incident cancer men NMSC 43 million incident cases tracheal bronchus lung TBL cancer 15 million incident cases prostate cancer 13 million incident cases common cause cancer death DALYs men TBL cancer 13 million death 284 million DALYs liver cancer 572 000 death 152 million DALYs stomach cancer 542 000 death 122 million DALYs woman 2017 common incident cancer NMSC 33 million incident cases breast cancer 19 million incident cases colorectal cancer 819 000 incident cases leading cause cancer death DALYs woman breast cancer 601 000 death 174 million DALYs TBL cancer 596 000 death 126 million DALYs colorectal cancer 414 000 death 83 million DALYs national epidemiological profile cancer burden GBD study show large heterogeneities reflection different exposure risk factors economic settings lifestyles access care screening GBD study used policy maker stakeholder develop improve national local cancer control order achieve global target improve equity cancer care",
        "mesh_terms": [
            "Persons with Disabilities",
            "Global Burden of Disease",
            "Global Health",
            "Humans",
            "Incidence",
            "Neoplasms",
            "Quality-Adjusted Life Years"
        ],
        "source": "https://pubmed.ncbi.nlm.nih.gov/31560378/",
        "source_type": "Bangladesh-specific"
    },
    {
        "pmid": "31516106",
        "title": "A Cross-Sectional Investigation of the Quality of Selected Medicines for Noncommunicable Diseases in Private Community Drug Outlets in Cambodia during 2011-2013.",
        "abstract": "Although issue substandard falsified medicine quite well known research focused medicine used treat communicable diseases relatively little research carried quality medicine noncommunicable disease NCDs study designed assess quality seven widely used medicine NCDs Cambodia 20112013 Medicines collected private community drug outlet Phnom Penh urban area stratified random sampling Battambang Kandal Kampong Speu Takeo rural areas convenience sampling Samples subsequently analyzed visual inspection authenticity investigation pharmacopoeial analysis highperformance liquid chromatography Various discrepancy observed visual inspection package medicines 372 tabletcapsule sample 64 manufacturer 16 countries manufacturer confirmed 107 288 authentic authenticity sample could verified Three hundred sixtyfour 978 sample registered Cambodia Among samples 234 95 CI 192280 noncompliant one quality tests 129 95 CI 97167 contained amount active pharmaceutical ingredient outside permitted range including showing extreme deviations 14 95 CI 106179 failed content variation 108 95 CI 78144 failed meet pharmacopoeial reference range dissolution tests Pharmaceutical quality appeared unrelated storage conditions Although sample obviously falsified high prevalence substandard medicine NCDs Cambodia indicating need focused regulatory action including collaborative initiative manufacturers",
        "mesh_terms": [
            "Cambodia",
            "Commerce",
            "Counterfeit Drugs",
            "Cross-Sectional Studies",
            "Drug Contamination",
            "Drug Packaging",
            "Humans",
            "Noncommunicable Diseases",
            "Pharmaceutical Preparations",
            "Pharmacies",
            "Quality Control"
        ],
        "source": "https://pubmed.ncbi.nlm.nih.gov/31516106/",
        "source_type": "Bangladesh-specific"
    },
    {
        "pmid": "31455307",
        "title": "Type 2 diabetes mellitus in Bangladesh: a prevalence based cost-of-illness study.",
        "abstract": "economic burden type 2 diabetes adequately investigated many low lower middleincome countries including Bangladesh aim study estimate costofillness type 2 diabetes find determinant Bangladesh crosssectional study conducted 2017 recruit 1253 participant type 2 diabetes six diabetes hospitals providing primary tertiary health care services located northern central region Bangladesh structured questionnaire used facetoface interviewing collect nonclinical data Patients medical record reviewed clinical data hospital record reviewed hospitalisation data Cost calculated patients perspective using bottomup methodology direct cost patient indirect cost patient attendant calculated microcosting approach used calculate direct cost human capital approach used calculate indirect cost Median regression analysis performed identify determinant average annual cost Among participants 54 male mean ±SD age 551 ± 125 year duration diabetes 107 ± 77 years average annual cost US8647 per patient Medicine cost accounted 607 direct cost followed hospitalisation cost 277 average annual cost patient hospitalisation 42 time higher compared without hospitalisation females use insulin longer duration diabetes presence diabetes complication significantly related average annual cost per patient cost diabetes care considerably high Bangladesh primarily driven medicine hospitalisation costs Optimisation diabetes management positive lifestyle change urgently required prevention comorbidities complications turn reduce cost",
        "mesh_terms": [
            "Adult",
            "Aged",
            "Bangladesh",
            "Comorbidity",
            "Cost of Illness",
            "Cross-Sectional Studies",
            "Diabetes Complications",
            "Diabetes Mellitus, Type 2",
            "Drug Costs",
            "Female",
            "Humans",
            "Interviews as Topic",
            "Male",
            "Middle Aged",
            "Prevalence",
            "Qualitative Research",
            "Surveys and Questionnaires"
        ],
        "source": "https://pubmed.ncbi.nlm.nih.gov/31455307/",
        "source_type": "Bangladesh-specific"
    },
    {
        "pmid": "31366382",
        "title": "The haematological consequences of Plasmodium vivax malaria after chloroquine treatment with and without primaquine: a WorldWide Antimalarial Resistance Network systematic review and individual patient data meta-analysis.",
        "abstract": "Malaria cause reduction haemoglobin compounded primaquine particularly patient glucose6phosphate dehydrogenase G6PD deficiency aim study determine relative contribution red cell loss malaria primaquine patient uncomplicated Plasmodium vivax systematic review identified P vivax efficacy study chloroquine without primaquine published January 2000 March 2017 Individual patient data pooled using standardised methodology haematological response versus time quantified using multivariable linear mixed effect model nonlinear term time Mean difference haemoglobin treatment group day nadir day 42 estimated model total 3421 patient 29 study included 1692 495 normal G6PD status 1701 497 unknown status 28 08 deficient borderline individuals 1975 patient treated chloroquine alone mean haemoglobin fell 1222 gdL 95 CI 1193 1250 day 0 nadir 1164 gdL 1136 1193 day 2 rising 1288 gdL 1260 1317 day 42 comparison chloroquine alone mean haemoglobin 1446 patient treated chloroquine plus primaquine  013 gdL  027 001 lower day nadir p  0072 049 gdL 028 069 higher day 42 p  0001 day 42 patient recurrent parasitaemia mean haemoglobin concentration  072 gdL  090  054 lower patient without recurrence p  0001 Seven day starting primaquine G6PD normal patient 03 1389 risk clinically significant haemolysis fall haemoglobin  25  7 gdL 1 4389 risk fall haemoglobin  5 gdL Primaquine potential reduce malariarelated anaemia day 42 beyond preventing recurrent parasitaemia widespread implementation require accurate diagnosis G6PD deficiency reduce risk druginduced haemolysis vulnerable individuals trial registered PROSPERO CRD42016053312 date first registration 23 December 2016",
        "mesh_terms": [
            "Adult",
            "Anemia, Hemolytic",
            "Antimalarials",
            "Chloroquine",
            "Female",
            "Glucosephosphate Dehydrogenase Deficiency",
            "Hemolysis",
            "Humans",
            "Malaria, Vivax",
            "Male",
            "Middle Aged",
            "Plasmodium vivax",
            "Primaquine"
        ],
        "source": "https://pubmed.ncbi.nlm.nih.gov/31366382/",
        "source_type": "Bangladesh-specific"
    },
    {
        "pmid": "31190922",
        "title": "Self-medication of antibiotics: investigating practice among university students at the Malaysian National Defence University.",
        "abstract": "bBackgroundb Selfmedication drug alleviate symptom common global behavior helping relieve burden health services many drug eg antibiotic prescriptiononly Selfmedication antibiotic SMA irrational use drugs contributing microbial resistance increasing health care cost higher mortality morbidity study aimed assess SMA among university students bMethodsb crosssectional study conducted among medical nonmedical student National Defence University Malaysia validated instrument used gather data Ethics approval obtained Random universal sampling adopted SPSS 21 used data analysis bResultsb total 649 student participated study 485 male 515 female 393 reported selfmedicating antibiotics Penicillin doxycycline clarithromycin antibiotic used majority reporting adverse drug reactions Cost saving convenience principal reason SMA mainly obtained local retail pharmacies Despite medical student particularly senior better knowledge antibiotic use nonmedical students 89 research participant responded practicing SMA goodacceptable practice bConclusionb SMA common amongst Malaysian student and despite understanding SMA unwise even medical student selfmedicate",
        "mesh_terms": [],
        "source": "https://pubmed.ncbi.nlm.nih.gov/31190922/",
        "source_type": "Bangladesh-specific"
    },
    {
        "pmid": "31031031",
        "title": "The role of immune correlates of protection on the pathway to licensure, policy decision and use of group B Streptococcus vaccines for maternal immunization: considerations from World Health Organization consultations.",
        "abstract": "development group B Streptococcus GBS vaccine maternal immunization constitutes global public health priority prevent GBSassociated early life invasive disease stillbirth premature birth maternal sepsis adverse neurodevelopmental consequences reduce perinatal antibiotic use Sample size requirement conduct randomized placebocontrolled trial assess vaccine efficacy relevant clinical endpoints condition appropriate ethical standard care constitute significant obstacle pathway vaccine availability Alternatively indirect evidence protection based immunologic data vaccine seroepidemiological studies complemented data opsonophagocytic vitro assay animal models could considered pivotal data licensure subsequent confirmation effectiveness disease outcome postlicensure evaluations Based discussion initiated World Health Organization present key consideration potential role correlate protection towards accelerated pathway GBS vaccine licensure wide scale use Priority activity support progress regulatory policy decision outlined",
        "mesh_terms": [
            "Cost-Benefit Analysis",
            "Drug Approval",
            "Female",
            "Humans",
            "Infant, Newborn",
            "Infant, Newborn, Diseases",
            "Maternal Health",
            "Pregnancy",
            "Pregnancy Complications, Infectious",
            "Premature Birth",
            "Stillbirth",
            "Streptococcal Infections",
            "Streptococcal Vaccines",
            "Streptococcus agalactiae",
            "Vaccination",
            "World Health Organization"
        ],
        "source": "https://pubmed.ncbi.nlm.nih.gov/31031031/",
        "source_type": "Bangladesh-specific"
    },
    {
        "pmid": "30681305",
        "title": "Business of Health. International Healthcare.",
        "abstract": "",
        "mesh_terms": [
            "Africa",
            "Asia",
            "Bangladesh",
            "Biosimilar Pharmaceuticals",
            "Canada",
            "China",
            "Commerce",
            "Delivery of Health Care",
            "Drug Approval",
            "Drug Costs",
            "Drug Industry",
            "Drugs, Generic",
            "Economics, Pharmaceutical",
            "Europe",
            "Finland",
            "France",
            "Fraud",
            "Germany",
            "Health Care Reform",
            "Health Care Sector",
            "Humans",
            "India",
            "Insurance, Health",
            "Kenya",
            "North America",
            "Norway",
            "Pharmaceutical Preparations",
            "Philippines",
            "Prostheses and Implants",
            "Taxes",
            "United Kingdom"
        ],
        "source": "https://pubmed.ncbi.nlm.nih.gov/30681305/",
        "source_type": "Bangladesh-specific"
    },
    {
        "pmid": "30587297",
        "title": "Risk of Plasmodium vivax parasitaemia after Plasmodium falciparum infection: a systematic review and meta-analysis.",
        "abstract": "14day course primaquine used radical cure Plasmodium vivax Plasmodium ovale malaria only quantified risk P vivax parasitaemia treatment Plasmodium falciparum commonly used antimalarial drug assess potential benefit radical cure patient uncomplicated malaria coendemic regions systematic review metaanalysis searched MEDLINE Embase Web Science Cochrane Database Systematic Reviews prospective clinical study language published Jan 1 1960 Jan 5 2018 assessing drug efficacy patient uncomplicated P falciparum malaria country coendemic P vivax Studies included presence absence P vivax parasitaemia recorded treatment primary outcome risk P vivax parasitaemia day 7 day 42 initiation antimalarial treatment P falciparum pooled risk calculated randomeffects metaanalysis compared risk P vivax parasitaemia treatment different artemisininbased combination therapy ACTs study registered PROSPERO number CRD42017064838 153 891 screened study included analysis including 31 262 patient 323 sitespecific treatment groups 130 85 study AsiaPacific region 16 10 Americas seven 5 Africa risk P vivax parasitaemia day 42 5·6 95 CI 4·07·4 Isup2sup92·0 117 estimates risk P vivax parasitaemia 6·5 95 CI 4·68·6 region short relapse periodicity compared 1·9 0·44·0 region long periodicity greater treatment rapidly eliminated ACT 15·3 5·129·3 artemetherlumefantrine compared 4·5 1·29·3 dihydroartemisininpiperaquine 5·2 2·97·9 artesunatemefloquine Recurrent parasitaemia delayed patient treated ACTs containing mefloquine piperaquine compared artemetherlumefantrine day 63 risk vivax parasitaemia 15 ACTs assessed finding show high risk vivax parasitaemia treatment falciparum malaria particularly area short relapse periodicity rapidly eliminated treatment coendemic regions universal radical cure patient uncomplicated malaria potential substantially reduce recurrent malaria Australian National Health Medical Research Council Royal Australasian College Physicians Wellcome Trust Bill  Melinda Gates Foundation",
        "mesh_terms": [
            "Adolescent",
            "Adult",
            "Antimalarials",
            "Artemisinins",
            "Child",
            "Child, Preschool",
            "Coinfection",
            "Female",
            "Humans",
            "Malaria, Falciparum",
            "Malaria, Vivax",
            "Male",
            "Parasitemia",
            "Plasmodium falciparum",
            "Plasmodium vivax",
            "Quinolines",
            "Risk",
            "Treatment Outcome",
            "Young Adult"
        ],
        "source": "https://pubmed.ncbi.nlm.nih.gov/30587297/",
        "source_type": "Bangladesh-specific"
    },
    {
        "pmid": "30289078",
        "title": "Burden of Congenital Rubella Syndrome (CRS) in Bangladesh: Systematic Review of Existing Literature and Transmission Modelling of Seroprevalence Studies.",
        "abstract": "Congenital Rubella Syndrome CRS leading cause vaccinepreventable congenital anomalies Comprehensive countrylevel data burden CRS low middleincome countries Bangladesh scarce information essential assessing impact rubella vaccination programs aim systematically review literature epidemiology CRS estimate burden CRS Bangladesh conducted systematic review existing literature transmission modelling seroprevalence study estimate prevaccine period burden CRS Bangladesh OVID Medline 1948  23 November 2016 OVID EMBASE 1974  23 November 2016 searched using combination databasespecific controlled vocabulary free text terms used agestratified deterministic model estimate prevaccination burden CRS Bangladesh Ten article identified published 2000 2014 including seven crosssectional studies two case series one analytical casecontrol study Rubella seropositivity ranged 470 860 among age population Rubella seropositivity increased age Rubella seropositivity among woman childbearing age 810 overall estimated incidence CRS 0·99 per 1000 live births corresponds approximately 3292 CRS case annually Bangladesh estimated burden CRS Bangladesh prevaccination period high provide important baseline information assess impact costeffectiveness routine rubella immunisation introduced 2012 Bangladesh",
        "mesh_terms": [
            "Bangladesh",
            "Case-Control Studies",
            "Cost of Illness",
            "Cross-Sectional Studies",
            "Female",
            "Humans",
            "Incidence",
            "Pregnancy",
            "Pregnancy Complications, Infectious",
            "Rubella Syndrome, Congenital",
            "Seroepidemiologic Studies"
        ],
        "source": "https://pubmed.ncbi.nlm.nih.gov/30289078/",
        "source_type": "Bangladesh-specific"
    },
    {
        "pmid": "30266330",
        "title": "Morbidity and mortality due to shigella and enterotoxigenic Escherichia coli diarrhoea: the Global Burden of Disease Study 1990-2016.",
        "abstract": "Shigella enterotoxigenic Escherichia coli ETEC bacterial pathogen frequently associated diarrhoeal disease significant cause mortality morbidity worldwide Global Burden Diseases Injuries Risk Factors study 2016 GBD 2016 systematic scientific effort quantify morbidity mortality due 300 cause death disability aimed analyse global burden shigella ETEC diarrhoea according age sex geography year 1990 2016 modelled shigella ETECrelated mortality using Bayesian hierarchical modelling platform evaluates wide range covariates model type basis vital registration verbal autopsy data used compartmental metaregression tool model incidence shigella ETEC enforces association incidence prevalence remission basis scientific literature population representative surveys healthcare data calculated 95 uncertainty interval UIs point estimates Shigella second leading cause diarrhoeal mortality 2016 among ages accounting 212 438 death 95 UI 136 979326 913 13·2 9·217·4 diarrhoea deaths Shigella responsible 63 713 death 41 19193 611 among child younger 5 year frequently associated diarrhoea across adult age groups increasing elderly people broad geographical distribution ETEC eighth leading cause diarrhoea mortality 2016 among age groups accounting 51 186 death 26 75783 064 3·2 1·84·7 diarrhoea deaths ETEC responsible 4·2 2·26·8 diarrhoea death child younger 5 years health burden bacterial diarrhoeal pathogen difficult estimate Despite existing prevention treatment options remain major cause morbidity mortality globally Additional emphasis public health official needed reduction disease due shigella ETEC reduce disease burden Bill  Melinda Gates Foundation",
        "mesh_terms": [
            "Adolescent",
            "Adult",
            "Aged",
            "Aged, 80 and over",
            "Biostatistics",
            "Child",
            "Child, Preschool",
            "Cost of Illness",
            "Diarrhea",
            "Dysentery, Bacillary",
            "Enterotoxigenic Escherichia coli",
            "Epidemiologic Methods",
            "Escherichia coli Infections",
            "Female",
            "Global Health",
            "Humans",
            "Infant",
            "Infant, Newborn",
            "Male",
            "Middle Aged",
            "Prevalence",
            "Risk Factors",
            "Shigella",
            "Survival Analysis",
            "Young Adult"
        ],
        "source": "https://pubmed.ncbi.nlm.nih.gov/30266330/",
        "source_type": "Bangladesh-specific"
    },
    {
        "pmid": "30170987",
        "title": "Typhoid conjugate vaccines: a new tool in the fight against antimicrobial resistance.",
        "abstract": "Typhoid fever acute systemic infectious disease responsible estimated 1220 million illness 150 000 death annually March 2018 new recommendation issued programmatic use typhoid conjugate vaccine endemic countries Health economic analysis typhoid vaccine informed funding decision national policy regarding vaccine rollout However focusing averted typhoid case associated costs traditional costeffectiveness analysis might underestimate crucial benefit typhoid vaccination programmes potential effect typhoid vaccine treatment patient nonspecific acute febrile illness considered every true case typhoid fever three 25 patient without typhoid disease treated antimicrobial unnecessarily conservatively amounting 50 million prescription per year Antimicrobials suspected typhoid might therefore important selective pressure emergence spread antimicrobial resistance globally propose largescale aggressive typhoid vaccination programmesincluding catchup campaign child 15 year age vaccination lower incidence settingshave potential reduce overuse antimicrobial thereby reduce antimicrobial resistance many bacterial pathogens Funding body national government must therefore consider potential broad reduction antimicrobial use resistance decision related rollout typhoid conjugate vaccines",
        "mesh_terms": [
            "Adolescent",
            "Anti-Bacterial Agents",
            "Child",
            "Child, Preschool",
            "Cost-Benefit Analysis",
            "Drug Resistance, Bacterial",
            "Female",
            "Humans",
            "Incidence",
            "Infant",
            "Male",
            "Salmonella typhi",
            "Typhoid Fever",
            "Typhoid-Paratyphoid Vaccines",
            "Vaccination",
            "Vaccines, Conjugate"
        ],
        "source": "https://pubmed.ncbi.nlm.nih.gov/30170987/",
        "source_type": "Bangladesh-specific"
    },
    {
        "pmid": "30170949",
        "title": "Availability and affordability of essential medicines for diabetes across high-income, middle-income, and low-income countries: a prospective epidemiological study.",
        "abstract": "Data scarce availability affordability essential medicine diabetes aim examine availability affordability metformin sulfonylureas insulin across multiple region world explore effect medicine use Prospective Urban Rural Epidemiology PURE study participant aged 3570 year n156 625 recruited 110 803 households 604 community 22 countries availability presence dose medication pharmacy day audit medicine cost data collected pharmacy Environmental Profile Communitys Health audit tool primary analysis describe availability affordability metformin insulin also commonly used prescribed combination two medicine diabetes management two oral drugs metformin plus sulphonylurea either glibenclamide also known glyburide gliclazide one oral drug plus insulin metformin plus insulin Medicines defined affordable cost medicine less 20 capacitytopay the household income minus food expenditure analysis included data collected pharmacy data representative sample households Data availability ascertained pharmacy audit data cost medications cost data used estimate cost months supply essential medicine diabetes estimated affordability medicine using income data household surveys Metformin available 113 100 113 pharmacy highincome countries 112 88·2 127 pharmacy uppermiddleincome countries 179 86·1 208 pharmacy lowermiddleincome countries 44 64·7 68 pharmacy lowincome country excluding India 88 100 88 pharmacy India Insulin available 106 93·8 pharmacy highincome countries 51 40·2 pharmacy uppermiddleincome countries 61 29·3 pharmacy lowermiddleincome countries seven 10·3 pharmacy lowerincome countries 67 76·1 88 pharmacy India estimated 0·7 household highincome country 26·9 household lowincome country could afford metformin 2·8 household highincome country 63·0 household lowincome country could afford insulin Among 13 569 8·6 PURE participants reported diagnosis diabetes 1222 74·0 participant reported diabetes medicine use highincome country compared 143 29·6 participant lowincome countries multilevel models availability affordability significantly associated use diabetes medicines Availability affordability essential diabetes medicine poor lowincome middleincome countries Awareness global difference might importantly drive change access patient diabetes Full funding source listed end paper see Acknowledgments",
        "mesh_terms": [
            "Adult",
            "Aged",
            "Costs and Cost Analysis",
            "Diabetes Mellitus",
            "Drugs, Essential",
            "Economic Status",
            "Health Services Accessibility",
            "Humans",
            "Hypoglycemic Agents",
            "Insulin",
            "Metformin",
            "Middle Aged",
            "Prospective Studies",
            "Rural Population",
            "Sulfonylurea Compounds",
            "Urban Population"
        ],
        "source": "https://pubmed.ncbi.nlm.nih.gov/30170949/",
        "source_type": "Bangladesh-specific"
    },
    {
        "pmid": "30076604",
        "title": "The Global Wicked Problem of Corruption and Its Risks for Access to HIV/AIDS Medicines.",
        "abstract": "discus corruption affect access antiretroviral therapy ARVs globally Recent case theft ARVs collusion manipulation procurement found country Central African Republic Bangladesh Malawi Guinea show still much work done reduce risk corruption includes addressing structural weakness procurement mechanism supply chain management system health commodity medicines",
        "mesh_terms": [
            "Anti-HIV Agents",
            "Commerce",
            "Counterfeit Drugs",
            "Developing Countries",
            "Drug Costs",
            "Global Health",
            "HIV Infections",
            "Health Services Accessibility",
            "Humans",
            "Rate Setting and Review",
            "Theft"
        ],
        "source": "https://pubmed.ncbi.nlm.nih.gov/30076604/",
        "source_type": "Bangladesh-specific"
    },
    {
        "pmid": "30033231",
        "title": "The effect of chloroquine dose and primaquine on Plasmodium vivax recurrence: a WorldWide Antimalarial Resistance Network systematic review and individual patient pooled meta-analysis.",
        "abstract": "Chloroquine remains mainstay treatment Plasmodium vivax malaria despite increasing report treatment failure systematic review metaanalysis investigate effect chloroquine dose addition primaquine risk recurrent vivax malaria across different settings systematic review done MEDLINE Web Science Embase Cochrane Database Systematic Reviews identified P vivax clinical trial published Jan 1 2000 March 22 2017 Principal investigator invited share individual patient data pooled using standardised methods Cox regression analysis random effect study site used investigate role chloroquine dose primaquine use rate recurrence day 7 day 42 primary outcome review protocol registered PROSPERO number CRD42016053310 134 identified chloroquine studies 37 study from 17 countries 5240 patient included 2990 patient treated chloroquine alone 1041 34·8 received dose target 25 mgkg risk recurrence 32·4 95 CI 29·835·1 day 42 controlling confounders 5 mgkg higher chloroquine dose reduced rate recurrence overall adjusted hazard ratio AHR 0·82 95 CI 0·690·97 p0·021 child younger 5 year 0·59 0·410·86 p0·0058 Adding primaquine reduced risk recurrence 4·9 95 CI 3·17·7 day 42 lower chloroquine alone AHR 0·10 0·050·17 p0·0001 Chloroquine commonly underdosed treatment vivax malaria Increasing recommended dose 30 mgkg child younger 5 year could reduce substantially risk early recurrence primaquine given Radical cure primaquine highly effective preventing early recurrence may also improve blood schizontocidal efficacy chloroquineresistant P vivax Wellcome Trust Australian National Health Medical Research Council Bill  Melinda Gates Foundation",
        "mesh_terms": [
            "Adolescent",
            "Adult",
            "Aged",
            "Aged, 80 and over",
            "Antimalarials",
            "Child",
            "Child, Preschool",
            "Chloroquine",
            "Drug Resistance",
            "Drug Therapy, Combination",
            "Female",
            "Humans",
            "Infant",
            "Infant, Newborn",
            "Malaria, Vivax",
            "Male",
            "Middle Aged",
            "Plasmodium vivax",
            "Primaquine",
            "Recurrence",
            "Young Adult"
        ],
        "source": "https://pubmed.ncbi.nlm.nih.gov/30033231/",
        "source_type": "Bangladesh-specific"
    },
    {
        "pmid": "30021742",
        "title": "Two for the price of one: emerging carbapenemases in a returning traveller to New York City.",
        "abstract": "report case complex orthopaedic infection patient returning New York City Bangladesh involved serious motor vehicle accident developed extensive osteomyelitis carbapenemresistant iKlebsiella pneumoniaei isolate unique due coexistence New Delhi metalloβlactamase1 Oxacillinase type181 carbapenemases relatively uncommon North America presumably acquired Bangladesh Herein explore challenge associated management carbapenemresistant Enterobacteriaceae infections including limited available data effective antimicrobial therapy also highlight added value rapid diagnostic technology guiding clinical management Ultimately patient required aggressive surgical management combination therapy aztreonam ceftazidimeavibactam true source control favourable clinical outcome",
        "mesh_terms": [
            "Adult",
            "Anti-Bacterial Agents",
            "Azabicyclo Compounds",
            "Aztreonam",
            "Ceftazidime",
            "Drug Combinations",
            "Drug Resistance, Multiple, Bacterial",
            "Humans",
            "Klebsiella Infections",
            "Klebsiella pneumoniae",
            "Male",
            "Mucormycosis",
            "Osteomyelitis",
            "Pseudomonas Infections",
            "Pseudomonas aeruginosa",
            "Rhizopus",
            "Travel-Related Illness",
            "beta-Lactamase Inhibitors"
        ],
        "source": "https://pubmed.ncbi.nlm.nih.gov/30021742/",
        "source_type": "Bangladesh-specific"
    },
    {
        "pmid": "29925430",
        "title": "Quantifying primaquine effectiveness and improving adherence: a round table discussion of the APMEN Vivax Working Group.",
        "abstract": "goal eliminate malaria AsiaPacific 2030 require safe widespread delivery effective radical cure malaria October 2017 Asia Pacific Malaria Elimination Network Vivax Working Group met discus impediment primaquine PQ radical cure overcome methodological difficulty assessing clinical effectiveness radical cure salient discussion meeting involved 110 representative 18 partner country 21 institutional partner organization reported Context specific strategy improve adherence needed increase understanding awareness PQ within affected communities must include education health promotion programs Lessons learned disease program highlight package approach greatest potential change patient prescriber habits however optimizing component approach quantifying effectiveness challenging trial setting reactivity participant result patient altering behaviour creates inherent bias Although bias reduced integrating data collection routine health care surveillance systems come cost decreasing detection clinical outcomes Measuring adherence factor relate it also requires indepth understanding context underlying sociocultural logic support it Reaching elimination goal require innovative approach improve radical cure vivax malaria well method evaluate effectiveness",
        "mesh_terms": [
            "Antimalarials",
            "Asia",
            "Humans",
            "Malaria, Vivax",
            "Pacific Islands",
            "Plasmodium vivax",
            "Primaquine",
            "Treatment Adherence and Compliance",
            "Treatment Outcome"
        ],
        "source": "https://pubmed.ncbi.nlm.nih.gov/29925430/",
        "source_type": "Bangladesh-specific"
    },
    {
        "pmid": "29459592",
        "title": "Current Trends of Using Systemic Antifungal Drugs and their Comparative Efficacy in Tinea Corporis and Tinea Cruris in Outpatient Department of Dermatology in a Tertiary Level Hospital.",
        "abstract": "Tinea corporis  cruris one earliest known fungal infection common throughout world Although tinea corporis tinea cruris cause mortality cause morbidity pose major health problem study conducted evaluate Comparative Efficacy Terbinafine Fluconazole Treatment Tinea corporis Tinea cruris cross sectional comparative type analytical study carried department Pharmacology  Therapeutics collaboration Dermatology Venereology Mymensingh Medical College Hospital Mymensingh Bangladesh January 2016 December 2016 study 168 newly diagnosed Tinea corporis Tinea cruris patient purposively selected pattern comparative efficacy terbinafine fluconazole analyzed Among 168 patient patient presented tinea corporis 5833 patient belong 2130 year age group Male female ratio study 1151 study 143 patient treated fluconazole 50mg daily 4 week 25 patient treated terbinafine 250 mg daily 4 weeks 4 weeks improvement rate fluconazole 8602 terbinafine 9600 clinical score group 4th week treatment slight reduction clinical score terbinafine using group fluconazole using group difference two clinical score statistically significant p005 Although significant difference observed two group patient clinical aspect due lower price availability hospital suggested fluconazole suitable treatment tinea corporis tinea cruris",
        "mesh_terms": [
            "Adult",
            "Antifungal Agents",
            "Bangladesh",
            "Cross-Sectional Studies",
            "Female",
            "Humans",
            "Male",
            "Outpatients",
            "Tinea",
            "Young Adult"
        ],
        "source": "https://pubmed.ncbi.nlm.nih.gov/29459592/",
        "source_type": "Bangladesh-specific"
    },
    {
        "pmid": "29447176",
        "title": "Cost-effectiveness of prenatal food and micronutrient interventions on under-five mortality and stunting: Analysis of data from the MINIMat randomized trial, Bangladesh.",
        "abstract": "Nutrition intervention may favourable well unfavourable effects Maternal Infant Nutrition Interventions Matlab MINIMat early prenatal food micronutrient supplementation reduced infant mortality reported costeffective However multiple micronutrient MMS supplement associated increased risk stunted growth infancy early childhood unfavourable outcome included previous costeffectiveness analysis aim study evaluate whether MINIMat intervention remain costeffective view favourable decreased underfiveyears mortality unfavourable increased stunting outcomes Pregnant woman rural Bangladesh food insecurity still prevalent randomized early E usual U invitation given food supplementation daily dos 30 mg 60 mg iron 400 μg folic acid MMS 15 micronutrient including 30 mg iron 400 μg folic acid E reduced stunting 45 year compared U MMS increased stunting 45 year compared Fe60 combination EMMS reduced infant mortality compared UFe60 outcome measure used disability adjusted life year DALYs measure overall disease burden combine year life lost due premature mortality under fiveyear mortality year lived disability stunting Incremental cost effectiveness ratio calculated using cost data already published studies incrementing UFe60 standard practice EMMS one DALY could averted cost US24 favourable unfavourable outcome included analysis early prenatal food multiple micronutrient intervention remained highly cost effective seem meaningful public health perspective",
        "mesh_terms": [
            "Adult",
            "Bangladesh",
            "Child, Preschool",
            "Cost-Benefit Analysis",
            "Dietary Supplements",
            "Female",
            "Folic Acid",
            "Food Supply",
            "Growth Disorders",
            "Humans",
            "Infant",
            "Infant Mortality",
            "Infant Nutritional Physiological Phenomena",
            "Infant, Newborn",
            "Iron",
            "Male",
            "Micronutrients",
            "Nutrition Policy",
            "Pregnancy",
            "Prenatal Care",
            "Prenatal Nutritional Physiological Phenomena",
            "Trace Elements",
            "Vitamins"
        ],
        "source": "https://pubmed.ncbi.nlm.nih.gov/29447176/",
        "source_type": "Bangladesh-specific"
    },
    {
        "pmid": "29253412",
        "title": "Availability and affordability of blood pressure-lowering medicines and the effect on blood pressure control in high-income, middle-income, and low-income countries: an analysis of the PURE study data.",
        "abstract": "Hypertension considered important risk factor cardiovascular diseases control poor worldwide aimed assess availability affordability blood pressurelowering medicines association use medicine blood pressure control country varying level economic development analysed availability costs affordability blood pressurelowering medicine data recorded 626 community 20 country participating Prospective Urban Rural Epidemiological PURE study Medicines considered available present local pharmacy surveyed affordable combined cost less 20 households capacity pay related information availability affordability use medicine blood pressure control multilevel mixedeffects logistic regression models compared result highincome uppermiddleincome lowermiddleincome lowincome countries Data India presented separately large generic pharmaceutical industry higher availability medicine country economic level availability two class blood pressurelowering drug lower lowincome middleincome country except India highincome countries proportion community four drug class available 94 highincome country 108 115 communities 76 India 68 90 71 uppermiddleincome country 90 126 47 lowermiddleincome country 107 227 13 lowincome country nine 68 proportion household unable afford two blood pressurelowering medicine 31 lowincome country 1069 3479 households 9 middleincome country 5602 65 471 less 1 highincome country 44 10 880 Participants known hypertension community four drug class available likely use least one blood pressurelowering medicine adjusted odds ratio OR 2·23 95 CI 1·593·12 p0·0001 combination therapy 1·53 1·132·07 p0·054 blood pressure controlled 2·06 1·692·50 p0·0001 community blood pressurelowering medicine available Participants known hypertension household able afford four blood pressurelowering drug class likely use least one blood pressurelowering medicine adjusted 1·42 95 CI 1·251·62 p0·0001 combination therapy 1·26 1·081·47 p0·0038 blood pressure controlled 1·13 1·001·28 p0·0562 unable afford medicines large proportion community lowincome middleincome country access one blood pressurelowering medicine and available often affordable factor associated poor blood pressure control Ensuring access affordable blood pressurelowering medicine essential control hypertension lowincome middleincome countries Population Health Research Institute Canadian Institutes Health Research Heart Stroke Foundation Ontario Canadian Institutes Health Research Strategy Patient Oriented Research Ontario SPOR Support Unit Ontario Ministry Health LongTerm Care pharmaceutical company with major contribution AstraZeneca Canada Sanofi Aventis France Canada Boehringer Ingelheim Germany amd Canada Servier GlaxoSmithKline Novartis King Pharma national local organisation participating countries",
        "mesh_terms": [
            "Aged",
            "Antihypertensive Agents",
            "Developed Countries",
            "Developing Countries",
            "Female",
            "Humans",
            "Hypertension",
            "Income",
            "Male",
            "Middle Aged",
            "Treatment Outcome"
        ],
        "source": "https://pubmed.ncbi.nlm.nih.gov/29253412/",
        "source_type": "Bangladesh-specific"
    }
]